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A B S T R A C T
Background
Concern has been expressed about the relevance of secondary care studies to primary care patients specifically about the effectiveness
of antidepressant medication. There is a need to review the evidence of only those studies that have been conducted comparing
antidepressant efficacy with placebo in primary care-based samples.
Objectives
To determine the efficacy and tolerability of antidepressants in patients (under the age of 65 years) with depression in primary care.
Search methods
All searches were conducted in September 2007.
The Cochrane Depression, Anxiety and Neurosis Group (CCDAN) Controlled Trials Register was searched, together with a supple-
mentary search of MEDLINE, PsycINFO, EMBASE, LILACS, CINAHL and PSYNDEX. Abstracts of all possible studies for inclu-
sion were assessed independently by two reviewers. Further trials were sought through searching the reference lists of studies initially
identified and by scrutinising other relevant review papers. Selected authors and experts were also contacted.
Selection criteria
Studies were selected if they were randomised controlled trials of tricyclic antidepressants (TCAs) or selective serotonin reuptake
inhibitors (SSRIs) versus placebo in adults. Older patients (over 65 years) were excluded. Patients had to be recruited from a primary
care setting. For continuous outcomes the Hamilton Depression scale of the Montgomery Asberg Scale was requred.
Data collection and analysis
Data were extracted using data extraction forms by two reviewers independently, with disagreements resolved by discussion. A similar
process was used for the validity assessment. Pooling of results was done using Review Manager 5. The primary outcome was depression
reduction, based on a dichotomous measure of clinical response, using relative risk (RR), and on a continuous measure of depression
symptoms, using the mean difference (MD), with 95% confidence intervals (CI).
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Main results
There were fourteen studies (16 comparisons) with extractable data included in the review, of which ten studies examined TCAs, two
examined SSRIs and two included both classes, all compared with placebo. The number of participants in the intervention groups was
1364 and in the placebo groups 919. Nearly all studies were of short duration, typically 6-8 weeks. Pooled estimates of efficacy data
showed an RR of 1.24, 95% CI 1.11-1.38 in favour of TCAs against placebo. For SSRIs this was 1.28, 95% CI 1.15 to 1.43.. The
numbers needed to treat (NNT) for TCAs ranged from 7 to 16 {median NNT 9} patient expected event rate ranged from 63% to
26% respectively) and for SSRIs from 7 to 8 {median NNT 7} (patient expected event rate ranged from 48% to 42% respectively) .
The numbers needed to harm (NNH for withdrawal due to side effects) ranged from 4 to 30 for TCAs (excluding three studies with
no harmful events leading to withdrawal) and 20 to 90 for SSRIs.
Authors’ conclusions
Both TCAs and SSRIs are effective for depression treated in primary care.
P L A I N L A N G U A G E S U M M A R Y
Antidepressants versus placebo for depression in primary care
Depression in the primary care setting is very common. However, most systematic reviews of antidepressant treatment have included
trials conducted in secondary care settings. There has been doubt about the effectiveness of antidepressants in primary care, and hence
the impetus to do this review. Through extensive searches of the literature we found 14 studies conducted in adults (not the elderly) in
primary care setting, in which tricyclic antidepressants (TCAs) or selective serotonin reupdate inhibitors (SSRIs) were compared against
a placebo control group in the treatment of depression. The results showed that both TCAs and SSRIs were effective for depression.
Most of the studies were supported by funds from pharmaceutical companies and were of short duration. There appeared to be more
adverse effects with TCAs than with SSRIs, however rates of withdrawal from study medication due to adverse effects were very similar
between the two antidepressant classes. Adverse effects not leading to medication cessation seemed to be more common with TCAs
than SSRIs.
B A C K G R O U N D
Description of the condition
Depression is very common in primary care, with a 12-month
prevalence of 18.1% (including dysthymia 0.8%). There is con-
siderable overlap with anxiety and substance use (MAGPIE 2003).
Depression is also common in the community, with a 12-month
prevalence of 7.1% (Oakley-Browne 2006).
It is a paradox that whilst the vast majority of patients with clini-
cal depression are dealt with in primary care, most of the research
findings upon which decisions are made have involved secondary
care patients. This is important because research suggests that pa-
tients with depressive disorders in primary care have different ae-
tiology, pathophysiology and natural history from those of psy-
chiatric inpatients or outpatients (Arya 1999; Suh 1999). Often,
depressed primary care patients present with somatic symptoms,
which include gastrointestinal, skeletal muscle, and cardiovascu-
lar complaints, as opposed to describing non-somatic criteria for
depression.
Description of the intervention
The most commonly used antidepressants in the treatment of
depression in primary care are tricyclic antidepressants (TCAs)
and selective serotonin reuptake inhibitors (SSRIs). It is generally
thought that TCAs act by inhibiting the re-uptake by nerve cells
of the neurotransmitters norepinephrine, dopamine, or serotonin.
Tricyclics may have an affinity for muscarinic and histamine H1
receptors. Norepinephrine and dopamine are considered stimula-
tory neurotransmitters, but tricyclic antidepressants also increase
the effects H1 histamine, and hence have sedative effects. SSRIs
are a class of antidepressants used in the treatment of depression
and anxiety disorders. SSRIs increase the level of the serotonin by
inhibiting its reuptake into the presynaptic (brain) cell, increasing
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the level of serotonin available to bind to the postsynaptic recep-
tor.
Doubts about the effectiveness of antidepressant medication and
other therapies such as cognitive therapy may contribute to the
variability in primary care management of depression (Jenkins
2001; King 2002). Up to 40% of depressed patients fail to demon-
strate a response to first line antidepressant drug treatment (Joffe
1996) and of those that do respond only a proportion will achieve
full recovery (APA 1993). One cohort study of primary care pa-
tients found 60% of those treated with medication and 50% with
milder depression still met the criteria for depression at one year
(Goldberg 1998).
Why it is important to do this review
Recent calls indicate an urgent need to review the evidence of only
those studies that have been conducted concerning antidepressant
efficacy on primary care based samples (Gill 1997; NCCHTA
2000). Systematic reviews of antidepressant medication often in-
clude patients who are seen in outpatient facilities rather than be-
ing seen in primary care or at least recruited from primary care
(Ellis 2002). Concern has been expressed about the relevance of
secondary care studies to primary care patients (NCCHTA 2000;
Gill 1997).We are aware of only two published systematic reviews
on patients either seen or recruited in primary care. Both com-
pared newer antidepressants with older antidepressants (Mulrow
2000; MacGillivray 2003). The review by Mulrow and colleagues
(Mulrow 2000) had a small section on antidepressant drugs ver-
sus placebo but reviewed only four studies. The MacGillivray re-
view (MacGillivray 2003) compared SSRIs with TCAs, and hence
only commented on relative efficacy. Comparison with placebo
is needed to obtain absolute efficacy. A paper version of this
Cochrane review was published in 2005 (Arroll 2005). A review
of new generation antidepressants to the Food and Drug Admin-
istration found that they were only effective with those patients
with more severe depression (Kirsch 2008).
These considerations indicate a need to review the evidence of only
those studies that have been conducted comparing antidepressant
efficacy with placebo on primary care based samples (Gill 1997;
NCCHTA 2000).
O B J E C T I V E S
The aim of this review was to examine the efficacy and tolerability
of antidepressant medication compared with placebo in studies of
treating depression in adults aged less than 65 years in primary
care.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials only were included. Cross-over trials
were not included as the course of depression is neither fluctuat-
ing nor rapidly responsive to treatment and hence not considered
suitable for this method.
Types of participants
To be included in the review studies had to include adults of
18 years or older. Studies with a majority (more than 50%) of
participants over 65 years or under 18 years of age were excluded.
Patients were required to be recruited from a primary care clinic.
The diagnosis of unipolar depression was based on formal diag-
nostic interviews according to international criteria such as the
ICD (International Classification of Disease -WHO) or the DSM
(Diagnostic and Statistical Manual American Psychiatric Associ-
ation). Studies in which GPs thought the patient was depressed,
and that the symptoms warranted pharmacological therapy, were
also included.
A post hoc decision was made to exclude studies in which partic-




Antidepressants for inclusion in the review were tricyclic antide-
pressants (TCAs), selective serotonin reuptake inhibitors (SSRIs)
or tetracyclic medication (eg Mianserin) that are currently in use
in some countries. Tetracyclic medications were included in the
TCA group, as their side effect profile is similar to TCAs. Studies
were required to be of a duration of at least four weeks. A post hoc
decision was made that medication(s) needed to be regarded as in
current clinical use (in the view of review authors) to be included
in the review.
Studies involving monoamine oxidase inhibitors and serotonin-
norepinephrine reuptake inhibitors (SNRIs) were not included in
the review. In future updates of the review, a comparison of SNRI
medication versus placebo will be included.
Main comparisons
1. TCAs versus placebo
2. SSRIs versus placebo
Types of outcome measures
Only trials with extractable data were included in the review.
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Primary outcomes
The primary outcome was reduction in depression symptoms,
measured in the following ways:
1. Continuous outcomes, reported as reduction in depression
symptoms at post-treatment, in terms of validated depression rat-
ing scales (themost commonly usedwere theHamilton depression
rating scale {Hamilton 1960) and the Montgomery-Asberg scale
Montgomery 1979})
2. Dichotomous outcomes, reported as clinical response post-
treatment.Outcomeswere considered positive for remissionwhere
a 50% reduction from intimal score or a score of less than 8 on the
Hamilton Depression rating scale was achieved. Response ranged
from any response (sometimes unspecified) to full remission. A
similar approach is used with the Montgomery -Asberg scale. The
dichotomous outcomes were needed to generate numbers needed
to treat (NNT) values.
Secondary outcomes
1. Occurrence of adverse effects





Search methods for identification of studies
Electronic searches
An electronic search of the Cochrane Collaboration Depression,
Anxiety and Neurosis Controlled Trials Registers (CCDANCTR-
Studies, Appendix 1; CCDANCTR-References, Appendix 2) was
carried out.
These Registers incorporate results of the CCDAN Group-wide




Further trials were sought through searching the reference lists of
studies initially identified and by scrutinising other relevant review
papers.
Other sources
Authors of all selected papers were approached and asked if they
had or knew of unpublished studies or published studies that we
had not found.
Data collection and analysis
Selection of studies
Two of the reviewers (BA and SM) read all the abstracts and de-
cided which were relevant to the review.Where it was unclear from
the abstract if the study was relevant to this review a full paper was
reviewed
Data extraction and management
Review authors independently extracted the data and compared
their results.Disagreement onfindingswere discussed and resolved
through discussion. Formal data extraction sheets were not used.
Assessment of risk of bias in included studies
Methodological quality assessment
Assessment of methodological quality was performed using the
Quality Rating Scale (Moncrieff 2001) (see Table 1 for a descrip-
tion of each item on the scale). Seven key methodological items
from the QRS were also selected. To be a high quality study the
total score had to be ≥ 27 and to have no zero scores in any of
the seven key components of quality (see below). The seven items
were chosen as they were considered essential aspects of quality (a
score of 0 on any component indicates poor quality for that item,
2 indicates good quality).
Seven key QRS components included:
• Item 2 = Adequacy of sample size
• Item 5 = Allocation concealment
• Item 6 = Clear description of treatment
• Item 8 = Representative source of participants
• Item 9 = Use of diagnostic criteria or clear specification of
inclusion criteria.
• Item 15 = Details regarding number and reasons for
withdrawal by group.
• Item 16 = Outcome measures described clearly or use of
validated instrument
Risk of bias assessment
Item 5 of the QRS, allocation concealment, represented one do-
main of the Cochrane Risk of Bias tool (Higgins 2008). The Risk
of Bias tool covers a total of six domains (sequence generation,
allocation concealment, blinding of participants, personnel and
assessors, incomplete outcome data, selective outcome reporting
and other sources of bias), and is now recommended for assessing
risk of bias in studies included in Cochrane reviews. In future up-
dates of this review, studies will be assessed for risk of bias using
all domains of this tool.
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Measures of treatment effect
For continuous outcomes, the standardised mean difference
(SMD) was used when different depression questionnaires were
being used between studies in a comparison, and the mean dif-
ference was used when the same questionnaire was being used,
together with 95% confidence intervals (CI).
For dichotomous outcomes, a pooled risk ratio (RR) was calcu-
lated, together with a 95% CI. When overall results were signifi-
cant, the number needed to treat (NNT) or harm (NNH) to pro-
duce one outcome was calculated by combining the overall risk
ratio with an estimate of the prevalence of the event in the control
group of the trials.
Unit of analysis issues
Where one control group and two medications were used in a
study, the control group was split in half for both the numerator
and the denominator.
Dealing with missing data
There was no adjustment by the reviewers for intention to treat
(ITT) analysis. Unless study authors did an ITT analysis, the anal-
yses were done per protocol.
Continuous outcomes: where values weremissing, certain assump-
tions were made. Where results were not reported in tables or the
text but presented as graphs, the values were estimated from read-
ing the graph and included as “approximated” results. The results
of this line of sight method was agreed upon by two of the review
authors. Where standard errors (SE) or confidence intervals (CIs)
were reported, the SD was calculated from those figures. Where
standard deviations (SD) of final results were not stated, and SEs
and CIs were also not reported, baseline SDs or the highest SD
from all studies reviewed for the same variable and group (inter-
vention or control) was used. For HAMD scores, the highest value
for SD for placebo in the TCA studies was 9.6 (Blashki (75mg)
1971) and 7.3 for intervention arms in the TCA studies (Brink
1984). For MADRS scores, the highest values for SDs were 10.3
for the Sertraline arm (Wade 2002), 4.5 forMianserin arm and 9.1
for placebo (Malt 1999). These were baseline SDs and were used
when SDs in other studies were not reported in the corresponding
groups.
Dichotomous outcomes: The denominator for incidence of ad-
verse events was the number for which data were collected
(i.e.initial drop-outs for which there were no data were not in-
cluded). However the denominator for incidence of withdrawals
for any reason was the number randomised (i.e. including initial
drop-outs for which there were no data).
Assessment of heterogeneity
Statistical heterogeneity was formally tested using the natural ap-
proximate chi-square test, with the p-value conservatively set at
0.1. Heterogeneity was also tested using the I2 statistic, with I2
values over 50% indicating strong heterogeneity.
Assessment of reporting biases
Publication bias was assessed using a funnel plot in RevMan 5
(Figure 1).
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Figure 1. Funnel plot of comparison: 1 TCAs versus placebo, outcome: 1.2 Clinical response at post-
treatment.
Data synthesis
Random effects analysis was used if the I2 was greater than 50%.
Subgroup analysis and investigation of heterogeneity
Subgroup analyses were conducted for the following clinical char-
acteristics:
1. Dosage of antidepressant
2. UK based studies vs European and US based studies
Sensitivity analysis
Sensitivity analyses were performed to test the robustness of results
for the following internal validity criteria:
1. Use of approximated data versus non-approximated data
2. High quality (≥27 on QRS) versus low quality studies
3. Major depression diagnosis only
4. Different depression scales
5. Proportion of GP assessors (use of GP assessors was chosen for
one of the sensitivity analyses as it was thought that GPs may have
a different way of assessing depression than psychiatrists)
6. No competing interests
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
Following screening of abstracts obtained through the searches and
through reference lists, hard copies of 37 articles were obtained.
Of those, fourteen studies (16 different comparisons) met the full
inclusion criteria for the review.
Included studies
The studies are described individually in the Characteristics of
Included studies table.
Study design
All studies were randomised controlled trials.
Participants
The studies included in the review covered a range of depres-
sive disorders. One TCA study included only patients with major
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depressive disorder (Barge-Schaapveld 2002). Two studies of SS-
RIs included only patients with major depressive disorder (Lepola
2001 Citalopram; Lepola 2001 Escitalopram; Wade 2002), as did
one study with both TCA and SSRI arms (Doogan 1994).
Interventions
Ten trials (11 comparisons) examining TCAs were identified.
The TCA drugs included imipramine Barge-Schaapveld 2002;
Lecrubier 1997; Philipp 1999), amitriptyline (Blashki (75mg)
1971; Blashki (150 mg) 1971; Feighner 1979; Hollyman 1988;
Mynors-Wallis 1995;Thomson 1982), dothiepin (Thompson
1989); and mianserin (Brink 1984).
Two trials (three comparisons) examined an SSRI drug. The SSRIs
included citalopram (Lepola 2001 Citalopram) and escitalopram
(Lepola 2001 Escitalopram;; Wade 2002).
Two trials included both a TCA and an SSRI arm. Doogan 1994
compared sertraline and dothiepin against a placebo control. Malt
1999 examined sertraline and mianserin against placebo.
We found no trials in primary care for monoamine oxidase in-
hibitors and only one on venlafaxine. For the purposes of the cur-
rent version of the review, the focus is on TCAs and SSRIs.
Outcomes
For the continuous outcomes the two scales used and reported
were either the Hamilton rating scale for depression (HAMD) or
theMontgomery Asberg depression rating scale (MADRS). These
two rating scales were the ones most commonly used. Occasion-
ally others were reported (e.g. Lecrubier 1997 for discrete out-
comes). For consistency and for the purposes of comparison, we
used HAMD and MADRS data only.
Excluded studies
Twenty studies were excluded from the review which had been
identified through a search of the CCDAN Register as being of
potential relevance to the review and required investigationbeyond
the title and CCDAN coding provided. Studies excluded from the
review are listed in the Characteristics of excluded studies, with
reasons for exclusion.
Reasons included participants with physical comorbidities (n =
2); psychiatric comorbidity (e.g., both anxiety and depression)
(n= 1) or participants from mixed setting (e.g. both primary and
secondary care) (n=1).
In five cases, studies turned out not to have carried out in a primary
care setting, or to feature treatment delivered by psychiatrists and
not primary care staff. In a further five studies drugs were given
either as combined treatment or against non-eligible comparators
(of these, one study appeared to have a placebo arm but in fact
included two active treatment arms which were both also given
placebos) (O’Hara 1978). Two studies were related to other stud-
ies included within the review. On closer inspection one study
was found to have an inadequate design; one an inappropriate
drug (a monoamine oxidase inhibitor); one assessed outcomes on
the Leeds Depression Scale only, and one study involved a drug
we considered no longer to be in current clinical use (the TCA
iprindole) (Rickels 1968)).
Risk of bias in included studies
Allocation
Eight of the fourteen studies included in the reviewwere assessed as
having adequate allocation concealment (Barge-Schaapveld 2002;
Blashki (75mg) 1971/Blashki (150 mg) 1971; Doogan 1994;
Feighner 1979; Hollyman 1988;Malt 1999;Mynors-Wallis 1995,
Wade 2002)
Other sources of bias (see Table 2 for individual scores of each
study)
Sample size adequacy
Ten studies were considered to have an adequate sample size (
Barge-Schaapveld 2002; Blashki (75mg) 1971/Blashki (150 mg)
1971; Doogan 1994; Feighner 1979; Hollyman 1988; Lepola
2001 Citalopram/Lepola 2001 Escitalopram;Malt 1999;Mynors-
Wallis 1995; Philipp 1999; Wade 2002).
Clear description of treatment
All studies included in the review provided a clear description of
the antidepressant treatment and placebo groups.
Representative source of participants
Nine studies were considered to have described and recruited a rep-
resentative sample (Brink 1984; Doogan 1994; Hollyman 1988;
Lecrubier 1997; Malt 1999; Mynors-Wallis 1995; Philipp 1999;
Thompson 1989;Thomson 1982).
Use of diagnostic criteria
All studies used diagnostic criteria and specified the severity of
depression, with the exception of Blashki (75mg) 1971/Blashki
(150 mg) 1971 and Thomson 1982.
Withdrawals
All studies followed up withdrawals and included them in analyses
with the exception of Barge-Schaapveld 2002, Doogan 1994,
Mynors-Wallis 1995 and Thompson 1989.
Outcome measures
Only one study did not fully describe and use validated instru-
ments (Doogan 1994).
Effects of interventions
A fixed effect model was used for all analyses unless otherwise
stated. If the I-squared statististic was >50%, a random effects
model was used.
COMPARISON 1: TCAs VERSUS PLACEBO
Primary outcome
1. Reduction in depression symptoms at post-treatment
There were 12 studies included in this analysis and 13 compar-
isons (one study reported on two doses, Blashki (150 mg) 1971,
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Blashki (75mg) 1971, and hence is reported here as two arms ver-
sus placebo). The standardised mean difference (SMD) was -0.49
95% CI -0.67 to -0.32 (random effects) (Analysis 1.1).
2. Clinical response at post-treatment
There were 8 studies for this analysis with 8 comparisons. The
relative risk for benefit (response) was 1.24, 95% CI 1.11 to 1.38
(Analysis 1.2). Response ranged from any response to remission.
Secondary outcomes
1. Occurence of adverse effects at post-treatment
This forest plot reports the adverse effects not necessarily causing
withdrawal from the study for patients on tricyclic antidepressants.
The relative risk for harm was 2.01, (95% CI 1.59 to 2.55) (
Analysis 1.3).
2. Withdrawal from trials at post-treatment (Analysis 1.4)
For withdrawal from the study due to adverse effects for patients
on tricyclic antidepressants, the relative risk for harm was 2.14,
95% CI 1.41 to 3.26.
For withdrawal due to treatment failure for patients on tricyclic
antidepressants, there was a reduction in effect and hence a posi-
tive result suggesting more treatment failure in the placebo group,
reported as a relative risk less than one. The relative risk was 0.40,
95% CI 0.27 to 0.58.
For withdrawal due to any reason for patients on tricyclic antide-
pressants, the relative risk was 1.02, 95% CI 0.84 to 1.24.
3. Economic outcomes
No studies contributed economic data.
Reduction in depression symptoms:1-4 week time points
(Analysis 1.5)
One week: For these studies, the SMD was -0.2, 95% CI -0.59 to
0.18 (random effects).
Two weeks: For these studies, the SMD was -0.24, 95% CI -0.62
to 0.14 (random effects).
Three weeks: For these studies, the SMD was -0.38, 95% CI -
1.01 to 0.26 (random effects).
Four weeks: For these studies, the SMD was -0.50, 95% CI -0.78
to -0.23 (random effects)
Clinical response: 1-4 week time points (Analysis 1.6)
Two weeks: The Lecrubier 1997 study used the Clinical Global
Impression (CGI) scale to report percentage ’verymuch improved’
instead of using theMADRS. Therefore the CGI was used for this
analysis in this paper. The relative risk for benefit was 1.78, 95%
CI 0.87 to 3.64 (random effects).
Four weeks: For these studies, the relative risk for benefit was 1.66,
95% CI 0.75 to 3.70 (random effects).
Subgroup analyses
1. Dosage of TCAs
Reduction in depression symptoms (Analysis 1.7)
Dose >100mg per day: For these studies in which patients were
on more than 100mg per day of tricyclic antidepressant, the SMD
was -0.5, 95% CI -0.71 to -0.29 (random effects).
Dose ≤ 100 mg per day: For studies in which patients started
on 100mg or less per day of tricyclic antidepressant, only Blashki
(75mg) 1971 stayed at that dose. In Thompson 1989 the dose
started at 75mg of Dothiepin but could go up to 150mg per day
and for Philipp 1999 the starting dose of Imipramine was 50 mg
but could go to 100mg. The SMD was -0.51, 95%CI -0.80 to -
0.22 (random effects).
Dose ≤ 75 mg per day: For those studies with patients who stayed
on 75 mg or lower the SMD was -0.31, 95%CI -0.78 to 0.16
(random effects)
Clinical response (Analysis 1.8)
For these studies, patients needed to be on more than 100 mg
per day of tricyclic antidepressant and the outcomes were dichoto-
mous. The relative risk for benefit (a response) was 1.27, 95% CI
1.13 to 1.44.
2. UK vs USA/European-based studies
Reduction in depression symptoms (Analysis 1.9)
For patients recruited in theUnitedKingdom, themean difference
was -1.83, 95% CI -3.32 to -0.34 (random effects). For patients
recruited in the USA or Europe, the mean difference was -2.82,
95% CI -3.61 to -2.03 (random effects).
Clinical response (Analysis 1.10)
For patients recruited in the United Kingdom, the relative risk for
benefit was 1.28, 95% CI 1.11 to 1.49. For patients recruited in
the USA or Europe, the relative risk for benefit was 1.19, 95% CI
1.00 to 1.40.
Sensitivity analyses
1. Approximated vs non-approximated data
Reduction in depression symptoms (Analysis 1.11)
For approximated data, there were seven studies in the analysis,
with the approximations resulting from an “eyeball” reckoning
from a graph or use of standard deviations from other studies
where there were none reported. The SMD was -0.46, 95 %CI -
0.73 to -0.18 (random effects). For non-approximated data, the
SMD was -0.39, 95% CI -0.79 to 0.01.
Clinical response (Analysis 1.12)
For approximated data, the values obtained from studies were usu-
ally “eyeballed” from graphs in the paper.The relative risk for ben-
efit (a response) was 1.28, 95% CI 1.12 to 1.46. For non-approxi-
mated data, the relative risk for benefit (a response) was 1.17, 95%
CI 0.96 to 1.42.
2. High versus low quality studies
Reduction in depression symptoms (Analysis 1.13)
For high quality studies (quality score of 28 or more out of 44 and
no zeros on the seven key methodological items), the SMD was
-0.60, 95% CI -0.80 to -0.41(random effects). For low quality
studies, the SMD was -0.35, 95% CI -0.63 to -0.07 (random
effects).
Clinical response (Analysis 1.14)
For high quality studies, the relative risk for benefit was 1.31, 95%
CI 1.14 to 1.51. For low quality studies, the relative risk for benefit
was 1.11, 95% CI 0.94 to 1.32.
3. Major depression diagnosis
Reduction in depression symptoms (Analysis 1.15)
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For studies in which patients had a diagnosis of major depression,
the mean difference was -1.37, 95% CI -2.52 to -0.22.
4. Use of different depression scales
Reduction in depression symptoms (Analysis 1.16)
For studies using the Montgomery-Asberg scale, the mean differ-
ence was -1.24, 95% CI -2.90 to 0.42 (random effects). For stud-
ies using the Hamilton Depression Scale, the mean difference was
-3.17, 95% CI -3.94 to -2.39 (random effects). For studies where
the outcomes were continuous but included outcomes of remis-
sion (less than 8 on the Hamilton Depression Scale), the mean
difference was -3.38, 95% CI -4.48 to -2.29 (random effects).
Clinical response:greatly improved/remission (Analysis 1.17)
For studies in which patients had outcomes of greatly improved
or remission data, the relative risk for benefit was 1.29 95% CI
(1.11 to 1.50).
5. 50% or more GP assessors
Reduction in depression symptoms (Analysis 1.18)
.For studies in which at least half or more of the assessors were
primary care providers, the SMD was -0.48, 95% CI -0.62 to -
0.33.
Clinical response (Analysis 1.19)
For studies in which at least half or more of the assessors were
primary care providers, the relative risk for benefit (a response)
was 1.19, 95% CI 1.03 to 1.39.
6. Studies with no competing interest
Reduction in depression symptoms (Analysis 1.20)
For studies where no competing interest was expressed (i.e. no
pharmaceutical company), the SMD was -0.68, 95% CI -0.90 to
-0.47.
Clinical response (Analysis 1.21)
For studies in which no competing interest was expressed (i.e. no
pharmaceutical company), the relative risk for benefit was 1.59,
95% CI 1.28 to 1.96.
COMPARISON 2: SSRIs VERSUS PLACEBO
Primary outcome
1. Clinical response at post-treatment (Analysis 2.1)
There were four studies with dichotomous outcomes in this com-
parisons. One study examined two medications, Escitalopram and
Citalopram (Lepola 2001 Citalopram Lepola 2001 Escitalopram).
The relative risk for benefit was 1.28, 95% CI 1.15 to 1.43.
Secondary outcomes
1. Occurrence of adverse effects at post treatment (Analysis 2.2)
Adverse effects did not necessarily cause withdrawal from the study
for patients on SSRIs. The relative risk for harm was 1.08, 95%
CI 0.96 to 1.22.
2. Withdrawal from trials at post treatment (Analysis 2.3)
For withdrawal due to adverse effects for patients on SSRIs, the
relative risk for harm was 2.05, 95% CI 1.11 to 3.75.
For withdrawal due to treatment failure for patients on SSRIs, re-
ported as a reduction in effect and hence a positive result, suggest-
ing more treatment failure in the placebo group is reported as a
relative risk less than one, the relative risk was 0.51, 95% CI 0.34
to 0.78.
For withdrawal due to any reason for patients on SSRIs, the relative
risk was 1.02, 95% CI 0.72 to 1.44.
3. Ecomomic outcomes
No studies contributed data to this outcome
Subgroup analyses
1. Dosage of SSRIs
No subgroup analyses were performed due to lack of studies
2. UK versus USA/European studies (Analysis 2.4)
For UK trials, the relative risk for benefit was 1.37, 95% CI 1.13
to 1.66. For USA/European studies, the relative risk for benefit
was 1.25, 95% CI 1.08 to 1.44.
Sensitivity analyses
1. High quality studies (Analysis 2.5)
The relative risk for benefit for high quality studies only was 1.32,
95% CI 1.10 to 1.59.
2. Major depression diagnosis (Analysis 2.6)
For studies in which patients had a diagnosis of major depression,
the relative risk for benefit was 1.29, 95% CI 1.13 to 1.48.
3. Use of different depression scales
Reduction in depression symptoms (Analysis 2.7)
For the Montgomery-Asberg scale, standard deviations were only
available for the Malt study so those SDs were used for the other
studies. The SMD was -0.24, 95% CI -0.35 to -0.12.
Clinical response (Analysis 2.8)
For the Montgomery-Asberg scale(remission or improved), the
relative risk for benefit was 1.27, 95% 1.11 to 1.45).
Sensitivity analyses were not performed for approximated data,
use of >50% GP assessors or studies with no competing interest.
Publication bias
Results from the funnel plot showed that small studies with no ef-
fect were missing from the graph (Figure 1). This may reflect some
publication bias as such studies can be difficult to get published.
Summary of main results: NNT and NNH
The numbers needed to treat (NNT) for TCAs ranged from 7 to
16 {median NNT 9} patient expected event rate ranged from 63%
to 26% respectively) and for SSRIs from 7 to 8 {median NNT 7}
(patient expected event rate ranged from48% to 42% respectively)
. The numbers needed to harm (NNH for withdrawal due to side
effects) ranged from 4 to 30 for TCAs (excluding three studies
with no harmful events leading to withdrawal) and 20 to 90 for
SSRIs.
D I S C U S S I O N
Summary of main results
The review included 14 studies (16 comparisons), and the results
show that both TCAs and SSRIs are significantly more effective
than placebo for both discrete and continuous outcomes. Such
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analyses were significant whether theGPs were 50% ormore of the
assessors, the studies were UK or Europe/US-based, and where the
Hamilton depression scale was used, but not the Montgomery-
Asberg scale. For TCAs, the results were also positive when analy-
ses included studies that had remission as an outcome or a Hamil-
ton score of less than 8 as a marker of remission, and where no
commercial backing for the study was reported. The only analyses
which were not statistically significant were those for low quality
studies and for response after one, two and threes weeks of tri-
cyclic antidepressants. The responses were statistically significant
for four weeks after starting therapy. The results were also pos-
itive for the pooling of those studies that had doses of tricyclic
antidepressants at or under 100mg per day. The numbers needed
to treat to get an improvement was 6 to 16 for the TCAs (me-
dian NNT 9) and 7 to 8 for the SSRIs (median NNT 7). These
findings are comparable to other treatments in primary care and
likely to be acceptable to most primary care clinicians. The results
apply to major depressive disorder and heterogeneous depression
(commonly seen in primary care).
Adverse effects were statistically higher than placebo for both tri-
cyclic antidepressants and SSRIs except for withdrawal for any rea-
son. Withdrawal due to treatment failure was statistically greater
in the placebo group than the medication group for both classes of
medication. This is consistent with the evidence for effectiveness.
Overall completeness and applicability of
evidence
The review included studies with a range of depressed patients.
One TCA study included only patients with major depressive
disorder (Barge-Schaapveld 2002). Two studies of SSRIs in-
cluded only patients with major depressive disorder (Lepola 2001
Citalopram; Lepola 2001 Escitalopram; Wade 2002), as did one
study with both TCA and SSRI arms (Doogan 1994). As patients
in primary care settings have a range of depression severity the
generalisability of the results of these studies to primary care is
reasonable (Arroll 2002). Only one study conducted an analysis
of minor depression and this found that amitriptyline was supe-
rior to placebo in probable or definite major depression on the
Research Diagnostic Criteria, but not in minor depression (Paykel
1988) Amitriptyline was also superior to placebo in subjects with
initial scores on the Hamilton Depression Scale of 13-15, and 16
or more, but not with lower scores. The Paykell study (Hollyman
1988) indicates that tricyclic antidepressants are of considerable
benefit in relativelymild depressive disorders, except in themildest
range.
Quality of the evidence
There has been an issue that studies in primary care populations
may only benefit from antidepressant medication when it is given
by a psychiatrist. Our significant findings for continuous and dis-
crete outcomes contradict this. There is evidence in this review
that both TCAs and SSRIs are more effective than placebo in the
primary care setting. This needs to be tempered with the knowl-
edge that there may be some publication bias and that many of
the studies were small and of variable quality.
The majority of systematic reviews concerning antidepressant effi-
cacy fail to report a detailed examination of methodological qual-
ity and therefore fail to include such criteria when examining treat-
ment effects. This is important because bias in primary studies due
to poor methodological quality (e.g. selection bias, ascertainment
bias, inappropriate handling of withdrawals, protocol violations)
can lead to exaggeration of treatment effects. A study of trial qual-
ity in systematic reviews showed that if low quality studies were
included in pooled estimates of treatment effect there was a 30-
50% exaggeration of treatment effectiveness (Moher 1999). We
did not however, find any appreciable differences between effects
for the high quality studies compared with the lower quality stud-
ies other than a non-significant result for clinical responses in the
low quality studies. Another form of bias for meta-analysis is that
of publication bias. Our funnel plot suggests that small studies
with small effect sizes may be missing. This is consistent with a
review of all applications to the US FDA, which examined all
submitted trials of newer antidepressants. Their finding was that
when all studies were considered, the benefit of antidepressants
was much smaller than when only the published studies were con-
sidered (Kirsch 2002).
Agreements and disagreements with other
studies or reviews
We found only 14 studies (16 comparisons) based in primary care
that met inclusion criteria and provided evidence for the compar-
ative efficacy of TCAs and SSRIs versus placebo. In a previous
review of trials comparing SSRIs and TCAs in primary care, we
similarly found relatively few studies (MacGillivray 2003). This
compares with considerably larger numbers of studies conducted
with patients from all settings. Williams 2000 found 206 studies
comparing a newer antidepressant with an older (123 of which
involved an SSRI). They found a benefit for the newer antidepres-
sants of RR = 1.6 (95% CI 1.3 to 2.3). In a review including only
studies conducted within the USA, Steffens 1997 discovered 36
trials comparing a TCA drug with an SSRI. The majority of stud-
ies included in the present review were small phase three studies
supported by commercial funding. In fact all of the SSRI versus
placebo studies had some commercial involvement. Many studies
were of short duration, typically 6-8 weeks. Our findings are in
keeping with a review of 108 studies of newer antidepressants,
which found that both TCAs and SSRIs were effective in treating
depression (Anderson 2001).
Previous reviews have tended to show that SSRIs are generallymore
tolerable than TCAs, although evidence is conflicting. Meta-anal-
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yses using drop-out rates as an index of tolerability have varied in
their findings. Whilst one review (Song 1993) found no difference
in drop-out rates between SSRIs (32.3%) and TCAs (33.2%), an-
other (Anderson 1995) found a small but statistically significant
lower drop-out rate for SSRIs (30.8%) relative to TCAs (33.4%).
In our review focusing only on primary care treated samples, we
found drop-out rates due to adverse effects for SSRIs of 5.2% and
TCAs of 10.2%. In another review of antidepressants in primary
care the risk of withdrawal of patients due to side effects with SSRI
compared with TCAs was 0.6 (95% CI 0.6-0.88) (MacGillivray
2003). Primary care clinicians may be more likely than hospital
colleagues to alter therapy when side-effects are experienced, even
during clinical trials (Simon 2002).
Our finding of a significant benefit for low dose tricyclic antide-
pressants (i.e. ≤ 100mg per day) is consistent with a meta-analy-
sis of studies in all settings which found a benefit from low dose
tricyclic antidepressants (Furukawa 2002). Only one of the three
studies in our review was statistically significant which suggests
that larger trials are needed in the primary care setting to clarify
issues such as dose of antidepressants (Thompson 1989;Blashki
(75mg) 1971). The review of low dose studies found there was no
evidence of increased benefit with higher doses but there was an
increase in side effects. Our results were similar to that review, but
the increase in adverse effects was non-significant.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our results suggest that treating depression with antidepressants
is an appropriate activity in primary care. The evidence is clear
for major depression and levels of depression greater than minor
depression. Based on this evidence, tricyclic antidepressants could
be considered and the dose kept at or below 100mg per day, and
waiting at least 4 weeks for a response may be worth considering.
Both SSRIs and TCAs appear to be tolerable, but more adverse
effects can be expected with TCAs. The numbers needed to treat
(NNT) are between 6 and 16 for TCAs (median NNT 9) and 7
to 8 (median NNT 7) for SSRIs. An NNT of 7 means that one
patient will benefit from treatment and six will not although up
to half may get better on placebo. This is true in primary care
and secondary care. There is no dose information on SSRIs and
we cannot comment on the appropriate duration of treatment for
either TCAs or SSRIs.
Implications for research
Gaps in the literature include a lack of attention to the treatment of
specific diagnostic groups, in particular minor depression. Further
research is needed on these groups of patients in addition to longer
and larger trials of low dose TCAs. There is also a need for studies
to be conducted by agencies other than pharmaceutical companies
and to conduct studies in patients with lower levels of depression
i.e. minor depression.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Barge-Schaapveld 2002
Methods Imipramine vs placebo
randomised controlled trial (RCT) in eight primary care practices in Netherlands
Participants N = 63. Imipramine group n=32; Placebo group n=31. Inclusion criteria: Age 18-65 years. DSM-III-R/
DSM-IV diagnosis of current depressive disorder. Equal or greater than 18 on 17-item Hamilton Rating
Scale for Depression (HAMD) and a score of equal or greater than 4 on Clinical Global Impression scale
(CGI) Exclusion criteria: on psychotropics or major medical disorder
Interventions 50 mg Imipramine per day increasing to over 200 mg per day after 1 week. Duration 6 weeks with a
subsample going to 18 weeks
Outcomes 10 withdrew due to adverse effects: 6 on Imipramine and 4 on placebo. Results at 6 weeks: Imipramine
group n=23, HAMD mean=8.9 (SD 6.2), Placebo n=26, HAMD mean=12.5 (SD 6.3)
Notes Not clear who administered medication and outcome check list
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Blashki (150 mg) 1971
Methods Amitriptyline vs Amylobarbitone vs placebo
RCT involving 21 GPs in Melbourne over a 6 month period
Participants N = 82. Inclusion criteria: Women over 15 years (mean age 37.7), persistent lower mood with depressive
symptoms; sleep and appetite disturbances, loss of interest, inability to concentrate.Mean baselineHAMD
= 17.4 (SD4.9) Exclusion criteria: organic brain disorder, schizophrenia, epilepsy, alcoholism and mental
retardation
Interventions Amitriptyline 150 mg per day, amylobarbitone 150 mg/day and placebo for 4 weeks
Outcomes 23 drop outs. (82 started, 61 analysed) Results at 28 days: Amitriptyline 75mg n=13, HAMD mean=6.4
(SD 5.4), vs Amitriptyline 150 mg n=14, HAMD mean=5.1 (SD 4.9) vs Placebo n=18, HAMD mean=
11.4 (SD 9.6)
At one week: Amitripyline 75mg n=13, HAMD mean=11.2 (SD 3.9) vs Amitriptyline 150mg n=14,
HAMD mean=7.1 (SD 4.7) vs Placebo n=18, HAMD mean=14.2 (SD 6.2)
Side effects not leading to withdrawal included shakiness of legs or arms, dry mouth, blurred vision,
fuzziness in the head drowsiness, restlessness, headache, pain in stomach (no difference between groups).
Adverse effects leading to withdrawal (11/82): Amitriptyline 75mg/day (4),
Amitriptyline 150mg/day (3), Placebo (4)
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Blashki (150 mg) 1971 (Continued)
Notes Amitriptyline versus placebo.
Saw a psychiatrist for medication but also saw their GP during 4 weeks of study. Considered as being
conducted by a psychiatrist
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Blashki (75mg) 1971
Methods Amitriptyline vs Amylobarbitone vs placebo
RCT involving 21 GPs in Melbourne over a 6 month period
Participants N = 82. Inclusion criteria: Women over 15 years (mean age 37.7), persistent lower mood with depressive
symptoms; sleep and appetite disturbances, loss of interest, inability to concentrate.Mean baselineHAMD
= 17.4 (SD4.9) Exclusion criteria: organic brain disorder, schizophrenia, epilepsy, alcoholism and mental
retardation
Interventions Amitriptyline 75 mg per day, amylobarbitone 150 mg/day and placebo for 4 weeks
Outcomes 23 drop outs. (82 started, 61 analysed) Results at 28 days: Amitriptyline 75mg n=13, HAMD mean=6.4
(SD 5.4), vs Amitriptyline 150 mg n=14, HAMD mean=5.1 (SD 4.9) vs Placebo n=18, HAMD mean=
11.4 (SD 9.6)
At one week: Amitripyline 75mg n=13, HAMD mean=11.2 (SD 3.9) vs Amitriptyline 150mg n=14,
HAMD mean=7.1 (SD 4.7) vs Placebo n=18, HAMD mean=14.2 (SD 6.2)
Side effects not leading to withdrawal included shakiness of legs or arms, dry mouth, blurred vision,
fuzziness in the head drowsiness, restlessness, headache, pain in stomach (no difference between groups).
Adverse effects leading to withdrawal (11/82): Amitriptyline 75mg/day (4),
Amitriptyline 150mg/day (3), Placebo (4)
Notes Amitriptyline versus placebo.
Saw a psychiatrist for medication but also saw their GP during 4 weeks of study. Considered as being
conducted by a psychiatrist
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Brink 1984
Methods Mianserin vs placebo
RCT
Patients from a representative Dutch general practice
Participants N =52. Patients aged 18-65 years with a diagnosis of depressive disorder according to theMedical Research
Council criteria: persistent alteration of mood which exceeded customary sadness accompanied by one or
more of following: self deprecation with a morbid sense of guilt, sleep disturbance, hypochondriasis with
psychomotor retardation or agitation.
Mianserin n=27, placebo n=25
Exclusion: major illness, ECT or antidepressants in previous 6 months.
Only 3 patients in each group had HAMD scores <17
Interventions Mianserin 3 x 10 mg nightly increasing to 6x nightly or matching placebo. Could have oxazepam as a
hypnotic. Duration 4 weeks
Outcomes 29% (15) drop outs. 9 from Mianserin and 6 placebo. Intention to treat if stayed in trial up to 15 days:
N=24 in mianserin and 25 in placebo group. At day 28: Mianserin group HAMD mean 8.8 (SD 7.3) vs
Placebo HAMD mean 11.1 (SD 6.9). Mianserin effect was significant at day 7: Mianserin group N=26,
HAMD mean 14.9, (SD 3.8) vs Placebo N=25 HAMD mean 17.6 (SD 6.0) at day 7.
At day 14: Mianserin group N=24 HAMD mean 12.1 (SD 6.8) vs N=25, HAMD mean 14.1 (SD 7.0)
for Placebo.
At day 21: Mianserin group N=24, HAMD mean 10.9 (SD 7.7) vs N=25 HAMD mean 11.8 (SD 6.9)
for Placebo.
Clinical global impression score at baseline: Mianserin group mean 2.7 at day 0 and at day 28 mean 1.1
and for placebo at day 0 mean 2.8 and at day 28 mean 1.6. Global improvement score: Mianserin at day
28 mean was 2.0 and placebo 1.3 (P<0.05)
Notes Tetracyclic study.
Low powered study. Medication and assessments done by GPs
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Doogan 1994
Methods Sertraline vs dothiepin vs placebo.
Randomised controlled trial
Country: UK
Not sure how GPs were chosen
Participants N=308 patients randomized. Primary major depressive disorder according to DSM III-R aged over 18
years and have a score of 22 or more on MADRS and a severity score of 4 or more on the Clinical Global
Impression scale (CGI). Exclusions >35 on MADRS, risk of suicide, pregnancy, lactation, significant
physical illness, mania, benign prostatic hypertrophy, treatment with certain antihypertensive agents,
antihistamines or sympathomimetic, lithium in past 3 months, resistant depression (i.e. had 8 or more
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Doogan 1994 (Continued)
weeks with medication or had an episode lasting over 1 year), schizophrenia or organic brain disease,
epilepsy, other psychotropic medications
Interventions 7-14 days of single blind run in. Sertaline 50 mg and dothiepin 75mg for 14 days then double dose if
possible for 6 weeks
Outcomes 13% (39) not evaluable.
At day 42: for sertraline group MADRS mean 12.5 (SD not reported) n=83 vs dothiepin mean 14.2 (SD
4.5) n=96 and placebo mean 15.3 (SD not reported) n=90. SDs were not reported but SDs from Malt
1999 were used in analysis.
The proportion responding (i.e.: => 50% reduction in MADRS) Sertraline=50/83 (60.2%), Dothiepin
=48/96 (50%) & placebo 40/90 (44%). Median dose of sertraline was 50 mg and 150 mg of dothiepin.
Side effects: (mainly in central nervous system, peripheral nervous system and GI system)
33/99 Sertraline, 32/108 Dothiepin and placebo 28/101.
Adverse effects leading to withdrawal: 5/99 for sertraline 2/108 on dothiepin and 3/101 on placebo.
Treatment withdrawal for any reason: Sertraline 16/99
Dothiepin 12/108
Placebo 11/101
Notes Analysis was intention to treat after 1st return visit. GPs did the assessments and medication handling
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Feighner 1979
Methods Amitriptyline vs placebo
RCT from 4 physicians in private practice in USA + 2 other university clinics
Participants N=337 patients. 30% male. Mean age 40.2 yrs. Criteria of Feighner 1972 dysphoric mood + 5 of poor
appetite, weight loss, loss of energy, agitation or retardation, loss of interest, diminished sexual drive, self
reproach or guilt, poor concentration and thoughts of death or suicide. Also > 20 onHAMD, >14 on short
Beck and >8 on Covi scale. Exclusions: schizophrenia, alcoholism, hysteria, antisocial personality, serious
medical risks, no recent ECT or MAOI or tricyclic or tranquilliser within 5 days. 143 were unipolar and
33 bipolar. 161 not classified
Interventions Amitriptyline 25mg 4 tablets to start increasing to 5 or 6 tabs over 4 weeks. Same for placebo. Assessment
was by a psychiatrist
Outcomes 58 drop outs. Outcome: 50% reduction in HAMD score at end of study (approximated from graphs)
amitriptyline 37/53 vs 13/30 placebo improved. Assume mean baseline score HAMD =36 (fig 1). At 4
weeks: Amitriptyline group mean 15.2 (SD 7.3) n=53
vs placebo = mean 21 (SD 9.6) n= 30 (see assumptions for SD in text).
At 1 week: Amtriptyline HAMDmean 26.9 (SD 7.3) n=71 vs placebo HAMDmean 27 (SD 9.6) n=41.
At 2 weeks: Amitriptyline mean 21.2 (SD 7.3) n=60 vs Placebo mean 25.7 (SD 9.6) n=35.
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Feighner 1979 (Continued)
The mean dose for Amitriptyline was 4.6 tablets;
placebo 5.5 tablets.
Side effects not necessarily leading to treatment withdrawal: Amitriptyline 12/93 and 3/50 for placebo.
Actual effects not stated. Withdrawal due to treatment failure: Amitriptyline 6/93 and placebo 9/50.
Treatment withdrawal for any reason: Amitriptyline 40/93 and 20/50 for placebo
Notes TCA vs placebo
Assessments all done by a psychiatrist but presumed patients came from primary care although cannot be
certain
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Hollyman 1988
Methods Amitriptyline vs placebo
RCT
41 GPs in UK
Participants N=178 Amitriptyline n=67, placebo n=74; 18-64 yrs
Research diagnostic criteria for major, minor or intermittent depression HAMD score >=6.
Exclusions: referral to a psychiatrist, antidepressant in previous 3 months, drug/alcohol problems, phobic,
Generalised Anxiety Disorder (GAD), Obsessive Compulsive Disorder (OCD), HAMD >=27
Major depression: 67% of intervention group, 74% placebo;
Minor or intermittent 33% in intervention group, 26% in placebo group
Interventions Amitriptyline 75mg in first week then 100mg for second week, increasing to 125-175 mg if needed.
Cointervention with benzodiazepines was allowed.
Psychiatrist did all assessments as home visits.
Outcomes 21% (37) drop outs at 4 weeks.
Intention to treat analysis of the 141 remaining.
Results at 6 weeks:
HAMDmean reduction 9.3 in Amitriptyline group and 6.1 in placebo group. Mean difference 3.2 (95%
CI 1.3-5 P<0.001); HAMD mean 5.4 (SD 3.8), n=67 in Amitriptyline group vs mean 8.7 (SD 9.6) n=
74 in placebo group at 6 weeks.
At 1 week: HAMD mean 11 (SD 3.8) n=67 vs mean 13.5 (SD 3.5) n=74 in placebo group.
At 2 weeks: mean 7.8 (SD 3.8) n= 67 in Amitriptyline group vs mean 10.4 (SD 3.5) n=74 in placebo
group.
At 3 weeks: mean 6.0, (SD 3.8) n=67 in Amitriptyline group vs mean 10.5 (SD 3.5) n=74 in placebo
group.
At 4 weeks: mean 5.0 (SD 3.8) n=67 vs mean 9.0 (SD 3.5) n=74 in placebo group.
Paykel et al 1988 found amitriptyline more effective for major depression (HAMD 13-24) than minor
depression (HAMD 6-12).
Adverse effects leading to withdrawal: 18/67 in amitriptyline group dropped out due to dry mouth,
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Hollyman 1988 (Continued)
increase in appetite and weight gain. 8/74 in placebo poor compliance and 3/74 withdrawal due to
treatment failure (worsening depression).
Withdrawal for any reason: 23/67 in amitriptyline group and 14/74 in the placebo group
Notes Psychiatrist did all interviews
Median dose Amitriptyline = 125mg
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Lecrubier 1997
Methods Venlafaxine vs Imipramine vs placebo
RCT
GP patients seen in outpatient clinic Patients probably from France, UK & Italy (24 study sites)
Participants N=229 Venlafaxine n=78, Imipramine n=74, placebo n=76. 18-65 year old men and women with de-
pressive symptoms for at least 2 weeks and regarded as needing antidepressant therapy, scored between 4
and 8 on the Raskin 3 areas scale and fulfilled the research diagnostic criteria (RDC) criteria for minor
14%, intermittent 7%, or major depression 79%. Exclusions: phobic anxiety, panic disorder, GAD,OCD,
schizophrenia, bipolar, pregnant or inadequate contraception, MADRS decreased >30% during screening
period, depression Newcastle Scale >7
Interventions 7-10 day washout period.
Medication day 1 was one 25 mg capsule of venlafaxine or imipramine or placebo; Day 2-4 1 capsule
twice daily; Days 5-7 3 caps daily. From day 8-15 two caps 3 times daily and to remain on this for the
remaining 13 week period. If the patients found the side effects intolerable could go to 1 cap 3 x daily
Outcomes 12% (27) drop outs. At week 13: no statistical difference on MADRS scale for imipramine vs placebo.
The proportion of responders on the MADRS > 50% = 66% (49/74) for imipramine and 63% (48/76)
for placebo.
Neither baseline nor end value standard deviations were reported so SDs from literature were used (see
assumptions in text). At week 1: n=74, MADRS mean 20.9 (SD 4.5) for imipramine group and n=76
MADRS mean 19.2 (SD 4.0) for placebo (p<0.05) At week 2: n=74 mean 18, (SD 4.5) for imipramine
group vs n=76mean16.2, (SD4.0) for placebo group. Atweek 3: n=74mean 16.4 (SD4.5) for Imipramine
vs n=76 mean 15.2 (SD 4). At week 4: n=74 mean 14 (SD 4.5) for Imipramine group vs n=76 mean 14.
2 (SD 4) for placebo group
Notes Treated by a psychiatrist.
Mean daily dose was 112mg imipramine
Risk of bias
Item Authors’ judgement Description
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Lecrubier 1997 (Continued)
Allocation concealment? Unclear B - Unclear
Lepola 2001 Citalopram
Methods Citalopram versus placebo
Double blind RCT from 8 countries including European countries and Canada
Includes the escitalopram arm
Participants N=314. (n=160 in citalopram group; n=154 in placebo group). Primary care patients 18-65 years and
fulfilling the DSM IV criteria for MDD with a baseline Montgomery Asberg rating of >=22 and <=
40. Patients mainly Caucasian, mean age 43 years (SD 11). Exclusions: schizophrenia, bipolar, OCD,
eating disorder, mental retardation, MADRS> or = 5 item 10 (suicidal thoughts), current treatment on
psychotropic drugs except benzodiazepines, ECT, psychotherapy or behavioural therapy
Interventions 20mg citalopram, which could be doubled at weeks 4 and 6
Outcomes Withdrawal for all reasons: Citalopram group 8/160 (5%), and 15/154 (10%) in placebo group.
Responders >=50% reduction in MADRS = 84/159 in citalopram group and 74/154 in placebo
Notes Intention to treat analysis with last observation carried forward
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - unclear
Lepola 2001 Escitalopram
Methods Escitalopram versus placebo
Double blind RCT from 8 countries including European countries and Canada
Includes the citalopram arm
Participants N=309 (10-20mg/day Escitalopram n=155; Placebo n=154). Primary care patients 18-65 years and ful-
filling the DSM IV criteria for MDD with a baseline Montgomery Asberg rating of >=22 and <=40.
Patients mainly Caucasian, mean age 43 years (SD 11).
Exclusions: schizophrenia, bipolar, OCD, eating disorder, mental retardation, MADRS>=5 on item 10
(suicidal thoughts), current treatment on psychotropic drugs except benzodiazepines, ECT, psychotherapy
or behavioural therapy
Interventions After 1 week of single blind placebo phase 8 weeks of 10mg/day Escitalopram or placebo. After 4-6 weeks
could double dose of drugs
Outcomes Withdrawal for all reasons 9/155 (6%) in Escitalopram group , and 15/154 (10%) in placebo group.
Responders >=50% reduction in MADRS =93/146 in Escitalopram group and 68/140 in placebo e group
On MADRS at the 8 week end of trial Escitalopram mean 14.2 (SD not reported) n=146; Citalopram
mean 15.4 (SD not reported) and n = 139; Placebo mean = 16.6 (SD not reported) n = 139
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Lepola 2001 Escitalopram (Continued)
Notes Intention to treat analysis with last observation carried forward
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Malt 1999
Methods Sertraline vs Mianserin vs placebo
RCT
Country: Norway from 61 GPs
Participants N=372. 18-79 years and symptoms of depression >2 weeks, severe enough to require treatment; Clinical
Global impression score of at least 3, >=20 on MADRS score, <25% reduction in MADRS score over
observation week. Exclusions: Dementia, schizophrenia, bipolar, organic mental disorder, not responding
before to amitriptyline 150mg per day or equivalent, previous failure to respond to SSRI or mianserin,
alcoholism, misuse of study drugs, Myocardial infarct in previous 3 months, epilepsy, hypotension, not
willing to use safe contraception.
86 to 89% of participants had major depression according to DSM III-R
Interventions All patients given emotional support and counselling from GPs.
Interventions: Sertraline 50 mg/day increased to 100 mg by 3rd week with tirations up to 150 mg after
4 weeks in non-responders to a maximum of 200 mg at 6 weeks.
Mianserin started at 30mg increased to 60 mg at 1 week then increasing if not responding to 90 mg/day
after 4 weeks to a maximum of 120 mg/day after 6 weeks if needed.
No information given about how the placebo was increased.
Given for 24 weeks
Outcomes 36% drop outs over 24 weeks. At follow up: MADRS for Sertraline group mean=11.9 (SD 10.3) n=122,
Mianserin group mean=11.3 (SD 9.1) n=121, and placebo group mean=14 (SD 10) n=129. The dose
was titrated up to 120mg/day. Baseline SDs used as approximations because SDs for outcome values not
published. Responders to treatment Sertraline (74/122), Mianserin = (65/121) and placebo = (60/129)
Notes Assumes that GPs gave the medication and did the assessments.
Average drug level of Sertraline was 114.6 mg/day and Mianserin 78 mg/day
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Mynors-Wallis 1995
Methods Amitriptyline vs placebo vs problem solving RCT. Participants selected from 26 GPs from 15 practices in
United Kingdom
Participants N=91 (82 in ITT analysis). 18-65 years with research diagnostic criteria (RDC) for major depression and
>=13 for HAMD score. Mean age 37-37.3 years in different groups and 23% male
Interventions 12 weeks of problem solving vs amitriptyline 150 mg/day vs placebo
Outcomes 29% drop outs. At 12-weeks: HAMD for amitriptyline group n=27, mean = 8.1 (SD 7.1) vs placebo n=
26, mean = 11.8 (SD 7.3)
Responders (HAMD <=7): 16/31 in Amitryptiline group, and 8/30 in placebo group. Mean dose
Amitriptyline was 139 mg/day.
Adverse effects leading to withdrawal: 3/31 for amitriptyline and 2/30 in the placebo group. Withdrawal
due to treatment failure: 1/31 for amitriptyline and 8/30 in the placebo group. Treatment withdrawal for
any reason: 6/31 for amitriptyline and 18/30 for placebo group
Notes 1 psychiatrist and 2 research GPs
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Philipp 1999
Methods Imipramine vs placebo vs hypericum extract
RCT. Participants selected from 18 general practitioners in Germany
Participants N=263 (251 in ITT analysis). Age 18-65 years (mean=47 years)
Imipramine n=105, placebo n=46, hypericum extract n=100.
ICD-10 moderate depressive episode, HAMD >=18, a clinical global impression rating of severity (item
1) of moderately, markedly or severely ill, depression duration of 4 weeks to 2 years. Exclusion: mild or
severe depressive disorder, bi-polar, alcohol or drug dependence, suicidal risk, long term use of lithium or
carbamazepine, other psychotropic drugs, > 3 months of benzodiazepines general or specific contraindi-
cations to imipramine
Interventions Patients screened for 1 week before treatment.
All patients treated with 3 capsules of trial drug daily.
Imipramine started at 50 mg on the first treatment day.75 mg days 2-4,then 100 mg. Identical placebo
for placebo and Hypericum. Duration 8 weeks
Outcomes 4.5% (12) drop outs.
At 8 weeks: HAMD mean = 8 (SD 4.2) n=109 in Imipramine group, and mean = 10.6 (SD 4.0) n=46 in
placebo group.
At 1 week: HAMD n=105 mean = 20.7 (SD 4.2) in Imipramine group vs n=46 mean = 19.2 (SD 4.0) in
placebo group.
At 2 weeks n=105 mean = 16.7 (SD 4.2) vs n=47 mean = 18 (SD 4.0).
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Philipp 1999 (Continued)
At 4 weeks: n=105 mean = 12.7 (SD 4.2) vs n=47 mean = 14.2 (SD 4.0).
Clinical Global Impression scale
proportion (much or very much) responding to Imipramine 70/105 and 29/46 in placebo group.
Side effects not necessarily leading to withdrawal: Imipramine 51/110 and 9/47 in placebo.
Any adverse events: 19% in placebo and 46% in imipramine group. Dry mouth: 13% in placebo and
38% in Imipramine group. Nausea: 2% in placebo and 11% in Imipramine group, Constipation: 6%
and 6%, respectively.
Headache: 2% and 6%.
Palpitations: 0% and 6%.
Dizziness 2% and 6%.
Adverse effects leading to withdrawal: 0/47 from placebo group and 1/110 from imipramine group
Notes Not clear who treated patients. Authors are either psychiatrists or psychologists.
Analysis was by Intention to treat
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Thompson 1989
Methods Dothiepin vs placebo.
RCT from 7 GPs in the United Kingdom
Participants N=52. (6 men and 46 women). Mean duration of depression 9.9 weeks. Diagnosed by GPs by their
usual criteria, not had treatment for depression in previous 6 months. Exclusions: pregnant, breastfeeding,
allergy to Dothiepin, glaucoma, urinary retention, epilepsy, cardiovascular disorder or impaired renal or
hepatic function.
Also excluded were antipsychotic treatment in the past 5 years, requiring referral to hospital or immediate
medication, or unlikely to be able to complete self rating questionnaires.
Participants were classified post-hoc into categories according to Research Diagnostic criteria for major
depression and endogenous depression and the Newcastle index for endogenous depression.
58% of patients had major depression.
Interventions 75mg of Dothiepin which could be increased to 150 mg after 2 weeks or placebo for 4 weeks. HAMD in
Dothiepin group mean = 6.6 (SD 7.3) n=20 & placebo group mean = 9.5 (SD 9.6) n=21
Outcomes 21% drop outs by 2 weeks. Using a last value carried forward there were 20 patients on Dothiepin and
21 patients on placebo. At 4 weeks: HAMD in Dothiepin group n=20 mean = 9.0 (SD 7.3) vs placebo
group n=21, mean = 10 (SD 9.6). At 3 weeks: n=21 mean = 9.5 (SD 7.3) vs n=20 mean = 10 (SD 9.6).
At 2 weeks the HAMD in the Dothiepin group n=20 mean = 11 (SD 7.3) vs placebo n= 21 mean = 11
(SD 9.6). At one week for Dothiepin n=20 mean =16, (SD 7.3) vs placebo n=21 mean = 15 (SD 9.6)
Notes GPs did the assessments. Patients in the study were very similar to patients given antidepressants in general
practice
The author is not sure if the data is available but is happy with our approximations of the SDs
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Thompson 1989 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Thomson 1982
Methods Amitriptyline vs placebo vs L-tryptophan vs combination L-tryptophan and amitriptyline
RCT in 5 Scottish group general practices.
Participants N=115. Amitriptyline n=31 placebo n=28 (2 other arms L-tryptophan n=29; combination Amitriptyline
+ L-tryptophan n=27)
127 women & 34 men. Patients 18-65 yrs
HMAD of ?12, depressed for? 2 weeks & considered by their GPs to need antidepressant medication but
not need psychiatric referral.
Exclusions:
Tricyclic antidepressants in previous 2 weeks or contraindications to tricyclics
Interventions 1 week run-in period then 25 mg amitriptyline 3x daily for 1 week then 2 tablets 3 x daily for remaining
11 weeks.
Could also take diazepam 5mg or nitrazepam as hypnotic but had to continue this throughout study.
2 other arms to study which involved amitriptyline + tryptophan & tryptophan. Only those on active
medication had blood levels for amitriptyline & tryptophan. 12 week duration
Outcomes 37% (43) drop outs.
At 12 weeks HAMD for amitriptyline group mean = 4.9 (SD 4.9) n=21 vs placebo group mean = 7.93
(SD 4.2) n=15.
At 4 weeks: Amitriptyline group n=26 mean = 6.85 (SD 7.3) vs placebo group n=19 mean = 11.55 (SD
9.6).
At 12 weeks: complete remission (i.e. a fall of 4 on HAMD) 67% (14/21) in amitriptyline group vs 33%
(5/15) in placebo group (estimates from graphs).
80% in active group had positive blood levels for amitriptyline.
Side effects not necessarily leading to withdrawal: amitriptyline 7/31 vs placebo 0/28
Adverse effects leading to withdrawal: amitriptyline 7/31 vs placebo 0/28
Withdrawal due to treatment failure: Amitriptyline 0/31 vs placebo 8/28
Treatment withdrawal for any reason: Amitriptyline 10/31 vs placebo 13/28
Notes Alternating visit assessments done by psychiatrist and patient’s own GP 2-weekly. Good correspondence
of assessments. Research psychiatrist ratings used in analysis (Weeks 0,4, 8 and 12)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Wade 2002
Methods Escitalopram vs placebo RCT in Canada, Estonia, France, Netherland, UK primary care in 40 centres
Participants N=380 (Escitalopram n=191, Placebo n=189). DSM IV major depression >=22 and <=40. Age 18-
65 years. Excluded: Schizophrenia, bipolar, OCD, mental retardation, suicidal thoughts. Psychotrophic
except benzodiazepines for insomnia
Interventions Escitalopram 10 mg vs placebo for 8 weeks
Outcomes 16% (60) drop outs.
At 8 weeks: Escitalopram n=191 MADRS mean = 14.3 (SD 9.1) vs placebo n=189 mean = 16.7 (SD 9.
1).
Responders: Escitalopram 55% (105/191) vs placebo 42% (79/189).
Side effects not necessarily leading to withdrawal: Escitalopram 59% (112/191) vs placebo 56% (105/
189). Adverse effects leading to withdrawal : Escitalopram 4.7% (9/191) vs 1.1% (2/189) for placebo.
Withdrawal due to treatment failure: 3.7% (7/191) for Escitalopram group vs 6.9% (13/189) for
placebo group.
Notes Not clear how administered the drugs and questionnaires
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Andersen 1993 Comorbidity (stroke)
Bakish 1992 Not a primary care setting
Barrett 1999 Study included secondary care patients as well as primary care patients
Barrrett 2001 Treatment in this study was undertaken by psychiatrists
Borsun 1992 Comborbidity (COPD)
Gomez 1968 Compared amitriptyline with an antipsychotic
Houston 1983 Used the Leeds depression scale
Jacobs 1965 A monoamine oxidase inhibitor
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(Continued)
Katz 2005 All medications combined, no single drug vs placebo
Laakman 1995 Patients from psychiatrists and outpatient clinics
Lehmann 1976 Not a true RCT (a CCT)
Montgomery 1998 Patients were from psychiatrists (i.e., not in primary care setting)
O’Hara 1978 Maprotiline compared with fluphenazine/nortriptyline; placebo was also used, but delivered in combination
with active treatments and not as a comparator
Paykel 1988 Primary data presented in Hollyman 1988 (see Characteristics of included studies table)
Rickels 1968 Iprindole not in current clinical use
Rickels 1971 No single antidepressant vs placebo
Rickels 1991 Not primary care setting
Schiffer 1975 No single antidepressant vs placebo
SCTG 1985 Patients were of a mixed population (both anxiety and depression)
Thompson 1994 Examined data originating from Doogan 1994 (included in this review)
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D A T A A N D A N A L Y S E S
Comparison 1. TCAs versus placebo




participants Statistical method Effect size
1 Depression symptoms at
post-treatment
13 1233 Std. Mean Difference (IV, Random, 95% CI) -0.49 [-0.67, -0.32]
2 Clinical response at
post-treatment
8 1058 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [1.11, 1.38]
3 Occurrence of adverse effects at
post-treatment
10 1015 Risk Ratio (M-H, Fixed, 95% CI) 2.01 [1.59, 2.55]
4 Withdrawal from trials at
post-treatment
13 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Adverse effects 11 1187 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [1.41, 3.26]
4.2 Treatment failure 8 769 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.27, 0.58]
4.3 Any reason 11 1027 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.84, 1.24]
5 Depression symptoms: 1-4 week
timepoints
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 1 week 8 691 Std. Mean Difference (IV, Random, 95% CI) -0.20 [-0.59, 0.18]
5.2 2 weeks 6 627 Std. Mean Difference (IV, Random, 95% CI) -0.24 [-0.62, 0.14]
5.3 3 weeks 5 464 Std. Mean Difference (IV, Random, 95% CI) -0.38 [-1.01, 0.26]
5.4 4 weeks 9 705 Std. Mean Difference (IV, Random, 95% CI) -0.50 [-0.78, -0.23]
6 Clinical response: 1-4 week
timepoints
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 2 weeks 3 304 Risk Ratio (M-H, Random, 95% CI) 1.78 [0.87, 3.64]
6.2 4 weeks 3 278 Risk Ratio (M-H, Random, 95% CI) 1.66 [0.75, 3.70]
7 Depression symptoms: dosage of
TCAs
13 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 >100mg per day 10 1028 Std. Mean Difference (IV, Random, 95% CI) -0.50 [-0.71, -0.29]
7.2 ≤100mg per day 3 223 Std. Mean Difference (IV, Random, 95% CI) -0.51 [-0.80, -0.22]
7.3 ≤75 mg per day 2 72 Std. Mean Difference (IV, Random, 95% CI) -0.31 [-0.78, 0.16]
8 Clinical response: dosage of
TCAs
7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 >100mg per day 7 907 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [1.13, 1.44]
9 Depression symptoms: UK vs
USA/European-based studies
11 Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 UK-based studies 6 607 Mean Difference (IV, Random, 95% CI) -1.83 [-3.32, -0.34]
9.2 USA or European-based
studies
5 581 Mean Difference (IV, Random, 95% CI) -2.82 [-3.61, -2.03]
10 Clinical response: UK vs
USA/European-based studies
8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 UK-based studies 5 574 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [1.11, 1.49]
10.2 USA or European-based
studies




13 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
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11.1 Approximated data 7 886 Std. Mean Difference (IV, Random, 95% CI) -0.46 [-0.73, -0.18]
11.2 Non-approximated data 6 347 Std. Mean Difference (IV, Random, 95% CI) -0.39 [-0.79, 0.01]
12 Clinical response: approximated
vs non-approximated data
8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 Approximated data 5 660 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [1.12, 1.46]
12.2 Non-approximated data 3 398 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.96, 1.42]
13 Depression symptoms: high vs
low quality studies
13 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 High quality studies 7 757 Std. Mean Difference (IV, Random, 95% CI) -0.60 [-0.80, -0.41]
13.2 Low quality studies 6 486 Std. Mean Difference (IV, Random, 95% CI) -0.35 [-0.63, -0.07]
14 Clinical response: high vs low
quality studies
8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 High quality studies 5 721 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [1.14, 1.51]
14.2 Low quality studies 3 337 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.94, 1.32]
15 Depression symptoms: major
depression diagnosis
2 235 Mean Difference (IV, Fixed, 95% CI) -1.37 [-2.52, -0.22]
16 Depression symptoms: use of
different depression scales
13 Mean Difference (IV, Random, 95% CI) Subtotals only
16.1 Montgomery-Asberg
scale
3 585 Mean Difference (IV, Random, 95% CI) -1.24 [-2.90, 0.42]
16.2 Hamilton Depression
Rating Scale
10 648 Mean Difference (IV, Random, 95% CI) -3.17 [-3.94, -2.39]
16.3 Hamilton Depression
Rating Scale for scores <8
4 222 Mean Difference (IV, Random, 95% CI) -3.38 [-4.48, -2.29]
17 Clinical response: greatly
improved/remission
5 752 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [1.11, 1.50]
18 Depression symptoms: 50% or
more GP assessors
7 765 Std. Mean Difference (IV, Fixed, 95% CI) -0.48 [-0.62, -0.33]
19 Clinical response: 50% or more
GP assessors
5 684 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [1.03, 1.39]
20 Depression symptoms: studies
with no competing interest
6 363 Std. Mean Difference (IV, Fixed, 95% CI) -0.68 [-0.90, -0.47]
21 Clinical response: studies with
no competing interest
3 285 Risk Ratio (M-H, Fixed, 95% CI) 1.59 [1.28, 1.96]
Comparison 2. SSRIs versus placebo




participants Statistical method Effect size
1 Clinical response at
post-treatment
5 1269 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [1.15, 1.43]
2 Occurrence of adverse effects at
post-treatment
3 831 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.87, 1.21]
3 Withdrawal from trials at
post-treatment
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Adverse effects 3 831 Risk Ratio (M-H, Fixed, 95% CI) 2.44 [1.22, 4.86]
3.2 Treatment failure 2 631 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.37, 0.86]
3.3 Any reason 2 580 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.80, 1.73]
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4 Clinical response: UK vs
USA/European-based studies
5 1269 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [1.15, 1.46]
4.1 UK-based studies 2 550 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [1.13, 1.66]
4.2 USA/European-based
studies
3 719 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [1.08, 1.44]
5 Clinical response: high quality
studies
2 424 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [1.10, 1.59]
6 Clinical response: major
depression diagnosis
4 1018 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [1.13, 1.48]
7 Depression symptoms: use of
Montgomery-Asberg scale
5 1239 Mean Difference (IV, Fixed, 95% CI) -2.20 [-3.29, -1.12]
8 Clinical response: use of
Montgomery-Asberg scale
5 1269 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [1.15, 1.43]
Analysis 1.1. Comparison 1 TCAs versus placebo, Outcome 1 Depression symptoms at post-treatment.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 1 TCAs versus placebo
Outcome: 1 Depression symptoms at post-treatment







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Barge-Schaapveld 2002 23 8.9 (6.2) 26 12.5 (6.3) 6.1 % -0.57 [ -1.14, 0.01 ]
Blashki (150 mg) 1971 14 5.1 (4.9) 9 11.4 (9.6) 3.3 % -0.86 [ -1.74, 0.02 ]
Blashki (75mg) 1971 13 6.4 (5.4) 9 11.4 (9.6) 3.3 % -0.65 [ -1.53, 0.22 ]
Brink 1984 24 8.8 (7.3) 25 11.1 (6.9) 6.3 % -0.32 [ -0.88, 0.25 ]
Doogan 1994 96 14.2 (4.5) 90 15.3 (4) 11.8 % -0.26 [ -0.55, 0.03 ]
Feighner 1979 53 15.2 (7.3) 30 21 (9.6) 7.9 % -0.70 [ -1.16, -0.24 ]
Hollyman 1988 67 5.4 (3.8) 74 8.7 (3.5) 10.4 % -0.90 [ -1.25, -0.55 ]
Lecrubier 1997 74 10.4 (4.5) 76 10.2 (4) 11.0 % 0.05 [ -0.27, 0.37 ]
Malt 1999 120 11.3 (4.5) 129 14 (4) 12.7 % -0.63 [ -0.89, -0.38 ]
Mynors-Wallis 1995 27 8.1 (7.1) 26 11.8 (7.3) 6.5 % -0.51 [ -1.05, 0.04 ]
Philipp 1999 105 8 (4.2) 46 10.6 (4) 10.2 % -0.62 [ -0.98, -0.27 ]
Thompson 1989 20 9 (7.3) 21 10 (9.6) 5.6 % -0.11 [ -0.73, 0.50 ]
Thomson 1982 21 4.9 (4.9) 15 7.93 (4.2) 4.9 % -0.64 [ -1.32, 0.04 ]
Total (95% CI) 657 576 100.0 % -0.49 [ -0.67, -0.32 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 24.09, df = 12 (P = 0.02); I2 =50%
Test for overall effect: Z = 5.45 (P < 0.00001)
-4 -2 0 2 4
Favours treatment Favours control
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Analysis 1.2. Comparison 1 TCAs versus placebo, Outcome 2 Clinical response at post-treatment.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 1 TCAs versus placebo
Outcome: 2 Clinical response at post-treatment
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Doogan 1994 48/96 40/90 16.2 % 1.13 [ 0.83, 1.53 ]
Feighner 1979 37/53 13/30 6.5 % 1.61 [ 1.03, 2.52 ]
Hollyman 1988 53/67 39/74 14.6 % 1.50 [ 1.17, 1.92 ]
Lecrubier 1997 49/74 48/76 18.6 % 1.05 [ 0.83, 1.33 ]
Malt 1999 65/121 60/129 22.8 % 1.15 [ 0.90, 1.48 ]
Mynors-Wallis 1995 16/31 8/30 3.2 % 1.94 [ 0.98, 3.84 ]
Philipp 1999 70/105 29/46 15.8 % 1.06 [ 0.82, 1.37 ]
Thomson 1982 14/21 5/15 2.3 % 2.00 [ 0.92, 4.35 ]
Total (95% CI) 568 490 100.0 % 1.24 [ 1.11, 1.38 ]
Total events: 352 (Treatment), 242 (Control)
Heterogeneity: Chi2 = 10.75, df = 7 (P = 0.15); I2 =35%
Test for overall effect: Z = 3.80 (P = 0.00014)
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Analysis 1.3. Comparison 1 TCAs versus placebo, Outcome 3 Occurrence of adverse effects at post-
treatment.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 1 TCAs versus placebo
Outcome: 3 Occurrence of adverse effects at post-treatment
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Barge-Schaapveld 2002 22/29 9/30 11.4 % 2.53 [ 1.41, 4.53 ]
Blashki (150 mg) 1971 3/14 2/9 3.1 % 0.96 [ 0.20, 4.69 ]
Blashki (75mg) 1971 4/13 2/9 3.0 % 1.38 [ 0.32, 6.02 ]
Brink 1984 19/27 7/25 9.4 % 2.51 [ 1.28, 4.93 ]
Doogan 1994 32/108 28/101 37.3 % 1.07 [ 0.70, 1.64 ]
Feighner 1979 12/93 3/50 5.0 % 2.15 [ 0.64, 7.27 ]
Malt 1999 18/121 6/129 7.5 % 3.20 [ 1.31, 7.79 ]
Philipp 1999 51/110 9/47 16.3 % 2.42 [ 1.30, 4.50 ]
Thompson 1989 14/20 5/21 6.3 % 2.94 [ 1.30, 6.66 ]
Thomson 1982 7/31 0/28 0.7 % 13.59 [ 0.81, 227.66 ]
Total (95% CI) 566 449 100.0 % 2.01 [ 1.59, 2.55 ]
Total events: 182 (Treatment), 71 (Control)
Heterogeneity: Chi2 = 14.45, df = 9 (P = 0.11); I2 =38%
Test for overall effect: Z = 5.78 (P < 0.00001)
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Analysis 1.4. Comparison 1 TCAs versus placebo, Outcome 4 Withdrawal from trials at post-treatment.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 1 TCAs versus placebo
Outcome: 4 Withdrawal from trials at post-treatment
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adverse effects
Barge-Schaapveld 2002 6/29 4/30 1.55 [ 0.49, 4.94 ]
Blashki (150 mg) 1971 3/16 2/9 0.84 [ 0.17, 4.15 ]
Blashki (75mg) 1971 4/13 2/9 1.38 [ 0.32, 6.02 ]
Brink 1984 1/27 0/25 2.79 [ 0.12, 65.38 ]
Doogan 1994 2/108 3/101 0.62 [ 0.11, 3.65 ]
Feighner 1979 12/93 3/50 2.15 [ 0.64, 7.27 ]
Lecrubier 1997 10/74 4/76 2.57 [ 0.84, 7.83 ]
Malt 1999 18/121 6/129 3.20 [ 1.31, 7.79 ]
Mynors-Wallis 1995 3/31 2/30 1.45 [ 0.26, 8.09 ]
Philipp 1999 1/110 0/47 1.30 [ 0.05, 31.28 ]
Thomson 1982 7/31 0/28 13.59 [ 0.81, 227.66 ]
Subtotal (95% CI) 653 534 2.14 [ 1.41, 3.26 ]
Total events: 67 (Treatment), 26 (Control)
Heterogeneity: Chi2 = 6.68, df = 10 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 3.56 (P = 0.00037)
2 Treatment failure
Blashki (150 mg) 1971 0/18 0/9 0.0 [ 0.0, 0.0 ]
Blashki (75mg) 1971 0/17 0/9 0.0 [ 0.0, 0.0 ]
Brink 1984 4/27 3/25 1.23 [ 0.31, 4.98 ]
Feighner 1979 6/93 9/50 0.36 [ 0.14, 0.95 ]
Lecrubier 1997 5/75 8/76 0.63 [ 0.22, 1.85 ]
Malt 1999 17/121 37/129 0.49 [ 0.29, 0.82 ]
Mynors-Wallis 1995 1/31 13/30 0.07 [ 0.01, 0.53 ]
Thomson 1982 0/31 8/28 0.05 [ 0.00, 0.88 ]
Subtotal (95% CI) 413 356 0.40 [ 0.27, 0.58 ]
Total events: 33 (Treatment), 78 (Control)
Heterogeneity: Chi2 = 8.68, df = 5 (P = 0.12); I2 =42%
0.1 0.2 0.5 1 2 5 10
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 4.80 (P < 0.00001)
3 Any reason
Barge-Schaapveld 2002 6/32 4/31 1.45 [ 0.45, 4.66 ]
Blashki (150 mg) 1971 4/18 3/12 0.89 [ 0.24, 3.28 ]
Blashki (75mg) 1971 4/17 3/12 0.94 [ 0.26, 3.46 ]
Brink 1984 9/27 6/25 1.39 [ 0.58, 3.34 ]
Doogan 1994 12/108 11/101 1.02 [ 0.47, 2.21 ]
Feighner 1979 40/93 20/50 1.08 [ 0.71, 1.62 ]
Hollyman 1988 28/90 24/88 1.14 [ 0.72, 1.81 ]
Lecrubier 1997 23/75 19/76 1.23 [ 0.73, 2.06 ]
Mynors-Wallis 1995 6/31 18/30 0.32 [ 0.15, 0.70 ]
Thompson 1989 14/25 9/27 1.68 [ 0.89, 3.18 ]
Thomson 1982 10/31 13/28 0.69 [ 0.36, 1.33 ]
Subtotal (95% CI) 547 480 1.02 [ 0.84, 1.24 ]
Total events: 156 (Treatment), 130 (Control)
Heterogeneity: Chi2 = 13.84, df = 10 (P = 0.18); I2 =28%
Test for overall effect: Z = 0.21 (P = 0.84)
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Analysis 1.5. Comparison 1 TCAs versus placebo, Outcome 5 Depression symptoms: 1-4 week timepoints.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 1 TCAs versus placebo
Outcome: 5 Depression symptoms: 1-4 week timepoints







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 1 week
Blashki (150 mg) 1971 14 7.1 (4.7) 9 14.2 (6.2) 8.2 % -1.29 [ -2.22, -0.35 ]
Blashki (75mg) 1971 13 11.2 (3.9) 9 14.2 (6.2) 8.8 % -0.58 [ -1.45, 0.29 ]
Brink 1984 26 14.9 (3.8) 25 17.6 (6) 12.3 % -0.53 [ -1.09, 0.03 ]
Feighner 1979 71 26.9 (7.3) 41 27 (9.6) 14.4 % -0.01 [ -0.40, 0.37 ]
Hollyman 1988 67 11 (3.8) 74 13.5 (3.5) 14.9 % -0.68 [ -1.02, -0.34 ]
Lecrubier 1997 74 20.9 (4.5) 76 19.2 (4) 15.1 % 0.40 [ 0.07, 0.72 ]
Philipp 1999 105 20.7 (4.2) 46 19.2 (4) 14.8 % 0.36 [ 0.01, 0.71 ]
Thompson 1989 20 16 (7.3) 21 15 (9.6) 11.6 % 0.11 [ -0.50, 0.73 ]
Subtotal (95% CI) 390 301 100.0 % -0.20 [ -0.59, 0.18 ]
Heterogeneity: Tau2 = 0.23; Chi2 = 37.24, df = 7 (P<0.00001); I2 =81%
Test for overall effect: Z = 1.04 (P = 0.30)
2 2 weeks
Brink 1984 24 12.1 (6.8) 25 14.1 (7) 14.8 % -0.29 [ -0.85, 0.28 ]
Feighner 1979 60 21.2 (7.3) 35 25.7 (9.6) 16.9 % -0.54 [ -0.97, -0.12 ]
Hollyman 1988 67 7.8 (3.8) 74 10.4 (3.5) 18.0 % -0.71 [ -1.05, -0.37 ]
Lecrubier 1997 74 18 (4.5) 76 16.2 (4) 18.3 % 0.42 [ 0.10, 0.74 ]
Philipp 1999 105 16.7 (4.2) 46 18 (4) 17.9 % -0.31 [ -0.66, 0.04 ]
Thompson 1989 20 11 (7.3) 21 11 (9.6) 14.1 % 0.0 [ -0.61, 0.61 ]
Subtotal (95% CI) 350 277 100.0 % -0.24 [ -0.62, 0.14 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 26.01, df = 5 (P = 0.00009); I2 =81%
Test for overall effect: Z = 1.23 (P = 0.22)
3 3 weeks
Brink 1984 24 10.9 (7.7) 25 11.8 (6.9) 18.3 % -0.12 [ -0.68, 0.44 ]
Feighner 1979 53 18 (7.3) 30 24 (9.6) 20.1 % -0.73 [ -1.19, -0.26 ]
Hollyman 1988 67 6 (3.8) 74 10.5 (3.5) 21.8 % -1.23 [ -1.59, -0.87 ]
Lecrubier 1997 74 16.4 (4.5) 76 15.2 (4) 22.5 % 0.28 [ -0.04, 0.60 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Thompson 1989 20 9.5 (7.3) 21 10 (9.6) 17.3 % -0.06 [ -0.67, 0.56 ]
Subtotal (95% CI) 238 226 100.0 % -0.38 [ -1.01, 0.26 ]
Heterogeneity: Tau2 = 0.46; Chi2 = 41.40, df = 4 (P<0.00001); I2 =90%
Test for overall effect: Z = 1.17 (P = 0.24)
4 4 weeks
Blashki (150 mg) 1971 14 5.1 (4.9) 9 11.4 (9.6) 7.8 % -0.86 [ -1.74, 0.02 ]
Blashki (75mg) 1971 13 6.4 (5.4) 9 11.4 (9.6) 7.9 % -0.65 [ -1.53, 0.22 ]
Brink 1984 24 8.8 (7.3) 25 11.1 (6.9) 11.0 % -0.32 [ -0.88, 0.25 ]
Feighner 1979 53 15.2 (7.3) 30 21 (9.6) 12.1 % -0.70 [ -1.16, -0.24 ]
Hollyman 1988 67 6 (3.8) 74 10 (3.5) 13.2 % -1.09 [ -1.45, -0.74 ]
Lecrubier 1997 74 14 (4.5) 76 14.2 (4) 13.6 % -0.05 [ -0.37, 0.27 ]
Philipp 1999 105 12.7 (4.2) 46 14.2 (4) 13.3 % -0.36 [ -0.71, -0.01 ]
Thompson 1989 20 9 (7.3) 21 10 (9.6) 10.5 % -0.11 [ -0.73, 0.50 ]
Thomson 1982 26 6.85 (7.3) 19 11.55 (9.6) 10.6 % -0.55 [ -1.16, 0.05 ]
Subtotal (95% CI) 396 309 100.0 % -0.50 [ -0.78, -0.23 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 22.36, df = 8 (P = 0.004); I2 =64%
Test for overall effect: Z = 3.55 (P = 0.00038)
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Analysis 1.6. Comparison 1 TCAs versus placebo, Outcome 6 Clinical response: 1-4 week timepoints.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 1 TCAs versus placebo
Outcome: 6 Clinical response: 1-4 week timepoints









Feighner 1979 30/60 10/35 60.5 % 1.75 [ 0.98, 3.13 ]
Lecrubier 1997 5/74 5/76 27.6 % 1.03 [ 0.31, 3.40 ]
Thomson 1982 8/31 1/28 12.0 % 7.23 [ 0.96, 54.20 ]
Subtotal (95% CI) 165 139 100.0 % 1.78 [ 0.87, 3.64 ]
Total events: 43 (Treatment), 16 (Control)
Heterogeneity: Tau2 = 0.13; Chi2 = 2.74, df = 2 (P = 0.25); I2 =27%
Test for overall effect: Z = 1.58 (P = 0.11)
2 4 weeks
Feighner 1979 37/53 14/30 50.2 % 1.50 [ 0.98, 2.28 ]
Lecrubier 1997 11/74 13/76 33.9 % 0.87 [ 0.42, 1.81 ]
Thomson 1982 17/26 2/19 16.0 % 6.21 [ 1.63, 23.73 ]
Subtotal (95% CI) 153 125 100.0 % 1.66 [ 0.75, 3.70 ]
Total events: 65 (Treatment), 29 (Control)
Heterogeneity: Tau2 = 0.33; Chi2 = 6.61, df = 2 (P = 0.04); I2 =70%
Test for overall effect: Z = 1.25 (P = 0.21)
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Analysis 1.7. Comparison 1 TCAs versus placebo, Outcome 7 Depression symptoms: dosage of TCAs.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 1 TCAs versus placebo
Outcome: 7 Depression symptoms: dosage of TCAs







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 >100mg per day
Barge-Schaapveld 2002 23 8.9 (6.2) 26 12.5 (6.3) 7.3 % -0.57 [ -1.14, 0.01 ]
Blashki (150 mg) 1971 14 5.1 (4.9) 18 11.4 (9.6) 5.2 % -0.78 [ -1.50, -0.05 ]
Brink 1984 24 8.8 (7.3) 25 11.1 (6.9) 7.5 % -0.32 [ -0.88, 0.25 ]
Doogan 1994 96 14.2 (4.5) 90 15.3 (4) 14.7 % -0.26 [ -0.55, 0.03 ]
Feighner 1979 53 15.2 (7.3) 30 21 (9.6) 9.6 % -0.70 [ -1.16, -0.24 ]
Hollyman 1988 67 5.4 (3.8) 74 8.7 (3.5) 12.7 % -0.90 [ -1.25, -0.55 ]
Lecrubier 1997 74 10.4 (4.5) 76 10.2 (4) 13.6 % 0.05 [ -0.27, 0.37 ]
Malt 1999 120 11.3 (4.5) 129 14 (4) 15.9 % -0.63 [ -0.89, -0.38 ]
Mynors-Wallis 1995 27 8.1 (7.1) 26 11.8 (7.3) 7.8 % -0.51 [ -1.05, 0.04 ]
Thomson 1982 21 4.9 (4.9) 15 7.93 (4.2) 5.7 % -0.64 [ -1.32, 0.04 ]
Subtotal (95% CI) 519 509 100.0 % -0.50 [ -0.71, -0.29 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 21.86, df = 9 (P = 0.01); I2 =59%
Test for overall effect: Z = 4.66 (P < 0.00001)
2 ≤100mg per day
Blashki (75mg) 1971 13 6.4 (5.4) 18 11.4 (9.6) 21.1 % -0.60 [ -1.33, 0.13 ]
Philipp 1999 105 8 (4.2) 46 10.6 (4) 51.5 % -0.62 [ -0.98, -0.27 ]
Thompson 1989 20 9 (7.3) 21 10 (9.6) 27.4 % -0.11 [ -0.73, 0.50 ]
Subtotal (95% CI) 138 85 100.0 % -0.51 [ -0.80, -0.22 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.06, df = 2 (P = 0.36); I2 =3%
Test for overall effect: Z = 3.44 (P = 0.00058)
3 ≤75 mg per day
Blashki (75mg) 1971 13 6.4 (5.4) 18 11.4 (9.6) 43.5 % -0.60 [ -1.33, 0.13 ]
Thompson 1989 20 9 (7.3) 21 10 (9.6) 56.5 % -0.11 [ -0.73, 0.50 ]
Subtotal (95% CI) 33 39 100.0 % -0.31 [ -0.78, 0.16 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.99, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
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Analysis 1.8. Comparison 1 TCAs versus placebo, Outcome 8 Clinical response: dosage of TCAs.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 1 TCAs versus placebo
Outcome: 8 Clinical response: dosage of TCAs
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 >100mg per day
Doogan 1994 48/96 40/90 19.3 % 1.13 [ 0.83, 1.53 ]
Feighner 1979 37/53 13/30 7.7 % 1.61 [ 1.03, 2.52 ]
Hollyman 1988 53/67 39/74 17.3 % 1.50 [ 1.17, 1.92 ]
Lecrubier 1997 49/74 48/76 22.1 % 1.05 [ 0.83, 1.33 ]
Malt 1999 65/121 60/129 27.1 % 1.15 [ 0.90, 1.48 ]
Mynors-Wallis 1995 16/31 8/30 3.8 % 1.94 [ 0.98, 3.84 ]
Thomson 1982 14/21 5/15 2.7 % 2.00 [ 0.92, 4.35 ]
Subtotal (95% CI) 463 444 100.0 % 1.27 [ 1.13, 1.44 ]
Total events: 282 (Treatment), 213 (Control)
Heterogeneity: Chi2 = 9.31, df = 6 (P = 0.16); I2 =36%
Test for overall effect: Z = 3.89 (P = 0.00010)
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Analysis 1.9. Comparison 1 TCAs versus placebo, Outcome 9 Depression symptoms: UK vs USA/European-
based studies.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 1 TCAs versus placebo
Outcome: 9 Depression symptoms: UK vs USA/European-based studies





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 UK-based studies
Doogan 1994 96 14.2 (4.5) 90 15.3 (4) 25.6 % -1.10 [ -2.32, 0.12 ]
Hollyman 1988 67 5.4 (3.8) 74 8.7 (3.5) 25.8 % -3.30 [ -4.51, -2.09 ]
Lecrubier 1997 74 10.4 (4.5) 76 10.2 (4) 24.2 % 0.20 [ -1.16, 1.56 ]
Mynors-Wallis 1995 27 8.1 (7.1) 26 11.8 (7.3) 7.9 % -3.70 [ -7.58, 0.18 ]
Thompson 1989 20 9 (7.3) 21 10 (9.6) 4.9 % -1.00 [ -6.21, 4.21 ]
Thomson 1982 21 4.9 (4.9) 15 7.93 (4.2) 11.6 % -3.03 [ -6.01, -0.05 ]
Subtotal (95% CI) 305 302 100.0 % -1.83 [ -3.32, -0.34 ]
Heterogeneity: Tau2 = 2.04; Chi2 = 16.94, df = 5 (P = 0.005); I2 =70%
Test for overall effect: Z = 2.41 (P = 0.016)
2 USA or European-based studies
Barge-Schaapveld 2002 23 8.9 (6.2) 26 12.5 (6.3) 12.2 % -3.60 [ -7.10, -0.10 ]
Brink 1984 24 8.8 (7.3) 25 11.1 (6.9) 10.1 % -2.30 [ -6.28, 1.68 ]
Feighner 1979 53 15.2 (7.3) 30 21 (9.6) 10.2 % -5.80 [ -9.76, -1.84 ]
Malt 1999 120 11.3 (4.5) 129 14 (4) 36.1 % -2.70 [ -3.76, -1.64 ]
Philipp 1999 105 8 (4.2) 46 10.6 (4) 31.4 % -2.60 [ -4.01, -1.19 ]
Subtotal (95% CI) 325 256 100.0 % -2.82 [ -3.61, -2.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.58, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 7.00 (P < 0.00001)
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Analysis 1.10. Comparison 1 TCAs versus placebo, Outcome 10 Clinical response: UK vs USA/European-
based studies.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 1 TCAs versus placebo
Outcome: 10 Clinical response: UK vs USA/European-based studies
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 UK-based studies
Doogan 1994 48/96 40/90 29.6 % 1.13 [ 0.83, 1.53 ]
Hollyman 1988 53/67 39/74 26.5 % 1.50 [ 1.17, 1.92 ]
Lecrubier 1997 49/74 48/76 33.9 % 1.05 [ 0.83, 1.33 ]
Mynors-Wallis 1995 16/31 8/30 5.8 % 1.94 [ 0.98, 3.84 ]
Thomson 1982 14/21 5/15 4.2 % 2.00 [ 0.92, 4.35 ]
Subtotal (95% CI) 289 285 100.0 % 1.28 [ 1.11, 1.49 ]
Total events: 180 (Treatment), 140 (Control)
Heterogeneity: Chi2 = 7.68, df = 4 (P = 0.10); I2 =48%
Test for overall effect: Z = 3.32 (P = 0.00089)
2 USA or European-based studies
Feighner 1979 37/53 13/30 14.4 % 1.61 [ 1.03, 2.52 ]
Malt 1999 65/121 60/129 50.5 % 1.15 [ 0.90, 1.48 ]
Philipp 1999 70/105 29/46 35.1 % 1.06 [ 0.82, 1.37 ]
Subtotal (95% CI) 279 205 100.0 % 1.19 [ 1.00, 1.40 ]
Total events: 172 (Treatment), 102 (Control)
Heterogeneity: Chi2 = 2.61, df = 2 (P = 0.27); I2 =23%
Test for overall effect: Z = 1.99 (P = 0.046)
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Analysis 1.11. Comparison 1 TCAs versus placebo, Outcome 11 Depression symptoms: approximated vs
non-approximated data.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 1 TCAs versus placebo
Outcome: 11 Depression symptoms: approximated vs non-approximated data







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Approximated data
Doogan 1994 96 14.2 (4.5) 90 15.3 (4) 17.1 % -0.26 [ -0.55, 0.03 ]
Feighner 1979 53 15.2 (7.3) 30 21 (9.6) 13.3 % -0.70 [ -1.16, -0.24 ]
Hollyman 1988 67 5.4 (3.8) 74 8.7 (3.5) 15.8 % -0.90 [ -1.25, -0.55 ]
Lecrubier 1997 74 10.4 (4.5) 76 10.2 (4) 16.4 % 0.05 [ -0.27, 0.37 ]
Malt 1999 120 11.3 (4.5) 129 14 (4) 17.8 % -0.63 [ -0.89, -0.38 ]
Thompson 1989 20 9 (7.3) 21 10 (9.6) 10.3 % -0.11 [ -0.73, 0.50 ]
Thomson 1982 21 4.9 (4.9) 15 7.93 (4.2) 9.2 % -0.64 [ -1.32, 0.04 ]
Subtotal (95% CI) 451 435 100.0 % -0.46 [ -0.73, -0.18 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 22.01, df = 6 (P = 0.001); I2 =73%
Test for overall effect: Z = 3.24 (P = 0.0012)
2 Non-approximated data
Barge-Schaapveld 2002 23 8.9 (6.2) 26 12.5 (6.3) 17.6 % -0.57 [ -1.14, 0.01 ]
Blashki (150 mg) 1971 14 5.1 (4.9) 9 11.4 (9.6) 10.7 % -0.86 [ -1.74, 0.02 ]
Blashki (75mg) 1971 13 6.4 (5.4) 9 11.4 (9.6) 10.7 % -0.65 [ -1.53, 0.22 ]
Brink 1984 24 8.8 (7.3) 25 11.1 (6.9) 17.8 % -0.32 [ -0.88, 0.25 ]
Mynors-Wallis 1995 26 11.8 (7.3) 27 8.1 (7.1) 18.3 % 0.51 [ -0.04, 1.05 ]
Philipp 1999 105 8 (4.2) 46 10.6 (4) 24.9 % -0.62 [ -0.98, -0.27 ]
Subtotal (95% CI) 205 142 100.0 % -0.39 [ -0.79, 0.01 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 13.83, df = 5 (P = 0.02); I2 =64%
Test for overall effect: Z = 1.89 (P = 0.059)
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Analysis 1.12. Comparison 1 TCAs versus placebo, Outcome 12 Clinical response: approximated vs non-
approximated data.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 1 TCAs versus placebo
Outcome: 12 Clinical response: approximated vs non-approximated data
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Approximated data
Feighner 1979 37/53 13/30 10.1 % 1.61 [ 1.03, 2.52 ]
Hollyman 1988 53/67 39/74 22.5 % 1.50 [ 1.17, 1.92 ]
Lecrubier 1997 49/74 48/76 28.7 % 1.05 [ 0.83, 1.33 ]
Malt 1999 65/121 60/129 35.2 % 1.15 [ 0.90, 1.48 ]
Thomson 1982 14/21 5/15 3.5 % 2.00 [ 0.92, 4.35 ]
Subtotal (95% CI) 336 324 100.0 % 1.28 [ 1.12, 1.46 ]
Total events: 218 (Treatment), 165 (Control)
Heterogeneity: Chi2 = 7.25, df = 4 (P = 0.12); I2 =45%
Test for overall effect: Z = 3.58 (P = 0.00035)
2 Non-approximated data
Doogan 1994 48/96 40/90 46.0 % 1.13 [ 0.83, 1.53 ]
Mynors-Wallis 1995 16/31 8/30 9.1 % 1.94 [ 0.98, 3.84 ]
Philipp 1999 70/105 29/46 44.9 % 1.06 [ 0.82, 1.37 ]
Subtotal (95% CI) 232 166 100.0 % 1.17 [ 0.96, 1.42 ]
Total events: 134 (Treatment), 77 (Control)
Heterogeneity: Chi2 = 2.72, df = 2 (P = 0.26); I2 =26%
Test for overall effect: Z = 1.57 (P = 0.12)
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Analysis 1.13. Comparison 1 TCAs versus placebo, Outcome 13 Depression symptoms: high vs low quality
studies.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 1 TCAs versus placebo
Outcome: 13 Depression symptoms: high vs low quality studies







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High quality studies
Blashki (150 mg) 1971 14 5.1 (4.9) 9 11.4 (9.6) 5.9 % -0.86 [ -1.74, 0.02 ]
Blashki (75mg) 1971 13 6.4 (5.4) 9 11.4 (9.6) 5.9 % -0.65 [ -1.53, 0.22 ]
Doogan 1994 96 14.2 (4.5) 90 15.3 (4) 21.1 % -0.26 [ -0.55, 0.03 ]
Feighner 1979 53 15.2 (7.3) 30 21 (9.6) 14.2 % -0.70 [ -1.16, -0.24 ]
Hollyman 1988 67 5.4 (3.8) 74 8.7 (3.5) 18.5 % -0.90 [ -1.25, -0.55 ]
Malt 1999 120 11.3 (4.5) 129 14 (4) 22.7 % -0.63 [ -0.89, -0.38 ]
Mynors-Wallis 1995 27 8.1 (7.1) 26 11.8 (7.3) 11.6 % -0.51 [ -1.05, 0.04 ]
Subtotal (95% CI) 390 367 100.0 % -0.60 [ -0.80, -0.41 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 8.98, df = 6 (P = 0.17); I2 =33%
Test for overall effect: Z = 6.03 (P < 0.00001)
2 Low quality studies
Barge-Schaapveld 2002 29 8.9 (6.2) 30 12.5 (6.3) 15.4 % -0.57 [ -1.09, -0.05 ]
Brink 1984 24 8.8 (7.3) 25 11.1 (6.9) 14.0 % -0.32 [ -0.88, 0.25 ]
Lecrubier 1997 74 10.4 (4.5) 76 10.2 (4) 24.6 % 0.05 [ -0.27, 0.37 ]
Philipp 1999 105 8 (4.2) 46 10.6 (4) 22.7 % -0.62 [ -0.98, -0.27 ]
Thompson 1989 20 9 (7.3) 21 10 (9.6) 12.5 % -0.11 [ -0.73, 0.50 ]
Thomson 1982 21 4.9 (4.9) 15 7.93 (4.2) 10.8 % -0.64 [ -1.32, 0.04 ]
Subtotal (95% CI) 273 213 100.0 % -0.35 [ -0.63, -0.07 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 10.05, df = 5 (P = 0.07); I2 =50%
Test for overall effect: Z = 2.46 (P = 0.014)
-4 -2 0 2 4
Favours treatment Favours control
44Antidepressants versus placebo for depression in primary care (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.14. Comparison 1 TCAs versus placebo, Outcome 14 Clinical response: high vs low quality
studies.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 1 TCAs versus placebo
Outcome: 14 Clinical response: high vs low quality studies
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 High quality studies
Doogan 1994 48/96 40/90 25.6 % 1.13 [ 0.83, 1.53 ]
Feighner 1979 37/53 13/30 10.3 % 1.61 [ 1.03, 2.52 ]
Hollyman 1988 53/67 39/74 23.0 % 1.50 [ 1.17, 1.92 ]
Malt 1999 65/121 60/129 36.0 % 1.15 [ 0.90, 1.48 ]
Mynors-Wallis 1995 16/31 8/30 5.0 % 1.94 [ 0.98, 3.84 ]
Subtotal (95% CI) 368 353 100.0 % 1.31 [ 1.14, 1.51 ]
Total events: 219 (Treatment), 160 (Control)
Heterogeneity: Chi2 = 5.17, df = 4 (P = 0.27); I2 =23%
Test for overall effect: Z = 3.74 (P = 0.00018)
2 Low quality studies
Lecrubier 1997 49/74 48/76 50.6 % 1.05 [ 0.83, 1.33 ]
Philipp 1999 70/105 29/46 43.1 % 1.06 [ 0.82, 1.37 ]
Thomson 1982 14/21 5/15 6.2 % 2.00 [ 0.92, 4.35 ]
Subtotal (95% CI) 200 137 100.0 % 1.11 [ 0.94, 1.32 ]
Total events: 133 (Treatment), 82 (Control)
Heterogeneity: Chi2 = 2.57, df = 2 (P = 0.28); I2 =22%
Test for overall effect: Z = 1.20 (P = 0.23)
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Analysis 1.15. Comparison 1 TCAs versus placebo, Outcome 15 Depression symptoms: major depression
diagnosis.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 1 TCAs versus placebo
Outcome: 15 Depression symptoms: major depression diagnosis





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Barge-Schaapveld 2002 23 8.9 (6.2) 26 12.5 (6.3) 10.8 % -3.60 [ -7.10, -0.10 ]
Doogan 1994 96 14.2 (4.5) 90 15.3 (4) 89.2 % -1.10 [ -2.32, 0.12 ]
Total (95% CI) 119 116 100.0 % -1.37 [ -2.52, -0.22 ]
Heterogeneity: Chi2 = 1.74, df = 1 (P = 0.19); I2 =43%
Test for overall effect: Z = 2.33 (P = 0.020)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 TCAs versus placebo, Outcome 16 Depression symptoms: use of different
depression scales.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 1 TCAs versus placebo
Outcome: 16 Depression symptoms: use of different depression scales





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Montgomery-Asberg scale
Doogan 1994 96 14.2 (4.5) 90 15.3 (4) 33.2 % -1.10 [ -2.32, 0.12 ]
Lecrubier 1997 74 10.4 (4.5) 76 10.2 (4) 31.0 % 0.20 [ -1.16, 1.56 ]
Malt 1999 120 11.3 (4.5) 129 14 (4) 35.7 % -2.70 [ -3.76, -1.64 ]
Subtotal (95% CI) 290 295 100.0 % -1.24 [ -2.90, 0.42 ]
Heterogeneity: Tau2 = 1.77; Chi2 = 11.27, df = 2 (P = 0.004); I2 =82%
Test for overall effect: Z = 1.47 (P = 0.14)
2 Hamilton Depression Rating Scale
Barge-Schaapveld 2002 23 8.9 (6.2) 26 12.5 (6.3) 8.5 % -3.60 [ -7.10, -0.10 ]
Blashki (150 mg) 1971 14 5.1 (4.9) 9 11.4 (9.6) 2.7 % -6.30 [ -13.08, 0.48 ]
Blashki (75mg) 1971 13 6.4 (5.4) 9 11.4 (9.6) 2.6 % -5.00 [ -11.92, 1.92 ]
Brink 1984 24 8.8 (7.3) 25 11.1 (6.9) 6.9 % -2.30 [ -6.28, 1.68 ]
Feighner 1979 53 15.2 (7.3) 30 21 (9.6) 7.0 % -5.80 [ -9.76, -1.84 ]
Hollyman 1988 67 5.4 (3.8) 74 8.7 (3.5) 26.1 % -3.30 [ -4.51, -2.09 ]
Mynors-Wallis 1995 27 8.1 (7.1) 26 11.8 (7.3) 7.2 % -3.70 [ -7.58, 0.18 ]
Philipp 1999 105 8 (4.2) 46 10.6 (4) 23.7 % -2.60 [ -4.01, -1.19 ]
Thompson 1989 20 9 (7.3) 21 10 (9.6) 4.4 % -1.00 [ -6.21, 4.21 ]
Thomson 1982 21 4.9 (4.9) 15 7.93 (4.2) 10.7 % -3.03 [ -6.01, -0.05 ]
Subtotal (95% CI) 367 281 100.0 % -3.17 [ -3.94, -2.39 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.45, df = 9 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 7.98 (P < 0.00001)
3 Hamilton Depression Rating Scale for scores <8
Blashki (150 mg) 1971 14 5.1 (4.9) 9 11.4 (9.6) 6.5 % -6.30 [ -13.08, 0.48 ]
Blashki (75mg) 1971 13 6.4 (5.4) 9 11.4 (9.6) 6.2 % -5.00 [ -11.92, 1.92 ]
Hollyman 1988 67 5.4 (3.8) 74 8.7 (3.5) 61.9 % -3.30 [ -4.51, -2.09 ]
Thomson 1982 21 4.9 (4.9) 15 7.93 (4.2) 25.4 % -3.03 [ -6.01, -0.05 ]
Subtotal (95% CI) 115 107 100.0 % -3.38 [ -4.48, -2.29 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.99, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 6.07 (P < 0.00001)
-10 -5 0 5 10
Favours treatment Favours control
47Antidepressants versus placebo for depression in primary care (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.17. Comparison 1 TCAs versus placebo, Outcome 17 Clinical response: greatly
improved/remission.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 1 TCAs versus placebo
Outcome: 17 Clinical response: greatly improved/remission
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hollyman 1988 37/67 23/74 14.2 % 1.78 [ 1.19, 2.66 ]
Lecrubier 1997 33/74 26/76 16.7 % 1.30 [ 0.87, 1.95 ]
Malt 1999 65/120 60/129 37.6 % 1.16 [ 0.91, 1.49 ]
Mynors-Wallis 1995 16/31 8/30 5.3 % 1.94 [ 0.98, 3.84 ]
Philipp 1999 70/105 29/46 26.2 % 1.06 [ 0.82, 1.37 ]
Total (95% CI) 397 355 100.0 % 1.29 [ 1.11, 1.50 ]
Total events: 221 (Treatment), 146 (Control)
Heterogeneity: Chi2 = 6.68, df = 4 (P = 0.15); I2 =40%
Test for overall effect: Z = 3.29 (P = 0.0010)
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Analysis 1.18. Comparison 1 TCAs versus placebo, Outcome 18 Depression symptoms: 50% or more GP
assessors.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 1 TCAs versus placebo
Outcome: 18 Depression symptoms: 50% or more GP assessors







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Brink 1984 24 8.8 (7.3) 25 11.1 (6.9) 6.7 % -0.32 [ -0.88, 0.25 ]
Doogan 1994 96 14.2 (4.5) 90 15.3 (4) 25.7 % -0.26 [ -0.55, 0.03 ]
Malt 1999 120 11.3 (4.5) 129 14 (4) 33.0 % -0.63 [ -0.89, -0.38 ]
Mynors-Wallis 1995 27 8.1 (7.1) 26 11.8 (7.3) 7.1 % -0.51 [ -1.05, 0.04 ]
Philipp 1999 105 8 (4.2) 46 10.6 (4) 17.1 % -0.62 [ -0.98, -0.27 ]
Thompson 1989 20 9 (7.3) 21 10 (9.6) 5.7 % -0.11 [ -0.73, 0.50 ]
Thomson 1982 21 4.9 (4.9) 15 7.93 (4.2) 4.6 % -0.64 [ -1.32, 0.04 ]
Total (95% CI) 413 352 100.0 % -0.48 [ -0.62, -0.33 ]
Heterogeneity: Chi2 = 6.23, df = 6 (P = 0.40); I2 =4%
Test for overall effect: Z = 6.37 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 TCAs versus placebo, Outcome 19 Clinical response: 50% or more GP
assessors.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 1 TCAs versus placebo
Outcome: 19 Clinical response: 50% or more GP assessors
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Doogan 1994 48/96 40/90 26.9 % 1.13 [ 0.83, 1.53 ]
Malt 1999 65/121 60/129 37.8 % 1.15 [ 0.90, 1.48 ]
Mynors-Wallis 1995 16/31 8/30 5.3 % 1.94 [ 0.98, 3.84 ]
Philipp 1999 70/105 29/46 26.2 % 1.06 [ 0.82, 1.37 ]
Thomson 1982 14/21 5/15 3.8 % 2.00 [ 0.92, 4.35 ]
Total (95% CI) 374 310 100.0 % 1.19 [ 1.03, 1.39 ]
Total events: 213 (Treatment), 142 (Control)
Heterogeneity: Chi2 = 4.67, df = 4 (P = 0.32); I2 =14%
Test for overall effect: Z = 2.32 (P = 0.020)
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Analysis 1.20. Comparison 1 TCAs versus placebo, Outcome 20 Depression symptoms: studies with no
competing interest.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 1 TCAs versus placebo
Outcome: 20 Depression symptoms: studies with no competing interest







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Blashki (150 mg) 1971 14 5.1 (4.9) 9 11.4 (9.6) 6.0 % -0.86 [ -1.74, 0.02 ]
Blashki (75mg) 1971 13 6.4 (5.4) 9 11.4 (9.6) 6.0 % -0.65 [ -1.53, 0.22 ]
Feighner 1979 53 15.2 (7.3) 30 21 (9.6) 21.8 % -0.70 [ -1.16, -0.24 ]
Hollyman 1988 67 5.4 (3.8) 74 8.7 (3.5) 38.4 % -0.90 [ -1.25, -0.55 ]
Mynors-Wallis 1995 27 8.1 (7.1) 26 11.8 (7.3) 15.4 % -0.51 [ -1.05, 0.04 ]
Thompson 1989 20 9 (7.3) 21 10 (9.6) 12.3 % -0.11 [ -0.73, 0.50 ]
Total (95% CI) 194 169 100.0 % -0.68 [ -0.90, -0.47 ]
Heterogeneity: Chi2 = 5.37, df = 5 (P = 0.37); I2 =7%
Test for overall effect: Z = 6.21 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.21. Comparison 1 TCAs versus placebo, Outcome 21 Clinical response: studies with no
competing interest.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 1 TCAs versus placebo
Outcome: 21 Clinical response: studies with no competing interest
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Feighner 1979 37/53 13/30 26.9 % 1.61 [ 1.03, 2.52 ]
Hollyman 1988 53/67 39/74 60.0 % 1.50 [ 1.17, 1.92 ]
Mynors-Wallis 1995 16/31 8/30 13.2 % 1.94 [ 0.98, 3.84 ]
Total (95% CI) 151 134 100.0 % 1.59 [ 1.28, 1.96 ]
Total events: 106 (Treatment), 60 (Control)
Heterogeneity: Chi2 = 0.52, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 4.25 (P = 0.000021)
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Analysis 2.1. Comparison 2 SSRIs versus placebo, Outcome 1 Clinical response at post-treatment.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 2 SSRIs versus placebo
Outcome: 1 Clinical response at post-treatment
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Doogan 1994 50/83 40/90 14.0 % 1.36 [ 1.01, 1.81 ]
Lepola 2001 Citalopram 84/159 37/77 18.1 % 1.10 [ 0.84, 1.45 ]
Lepola 2001 Escitalopram 99/155 37/77 18.0 % 1.33 [ 1.02, 1.73 ]
Malt 1999 74/122 60/129 21.2 % 1.30 [ 1.03, 1.65 ]
Wade 2002 103/188 79/189 28.7 % 1.31 [ 1.06, 1.62 ]
Total (95% CI) 707 562 100.0 % 1.28 [ 1.15, 1.43 ]
Total events: 410 (Treatment), 253 (Control)
Heterogeneity: Chi2 = 1.48, df = 4 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 4.34 (P = 0.000014)
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Analysis 2.2. Comparison 2 SSRIs versus placebo, Outcome 2 Occurrence of adverse effects at post-
treatment.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 2 SSRIs versus placebo
Outcome: 2 Occurrence of adverse effects at post-treatment
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Doogan 1994 33/99 28/101 19.0 % 1.20 [ 0.79, 1.83 ]
Malt 1999 12/122 6/129 4.0 % 2.11 [ 0.82, 5.46 ]
Wade 2002 105/191 112/189 77.0 % 0.93 [ 0.78, 1.10 ]
Total (95% CI) 412 419 100.0 % 1.03 [ 0.87, 1.21 ]
Total events: 150 (Treatment), 146 (Control)
Heterogeneity: Chi2 = 4.08, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 0.32 (P = 0.75)
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Analysis 2.3. Comparison 2 SSRIs versus placebo, Outcome 3 Withdrawal from trials at post-treatment.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 2 SSRIs versus placebo
Outcome: 3 Withdrawal from trials at post-treatment
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adverse effects
Doogan 1994 5/99 3/101 27.5 % 1.70 [ 0.42, 6.92 ]
Malt 1999 12/122 6/129 53.9 % 2.11 [ 0.82, 5.46 ]
Wade 2002 9/191 2/189 18.6 % 4.45 [ 0.97, 20.34 ]
Subtotal (95% CI) 412 419 100.0 % 2.44 [ 1.22, 4.86 ]
Total events: 26 (Treatment), 11 (Control)
Heterogeneity: Chi2 = 0.94, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.53 (P = 0.012)
2 Treatment failure
Malt 1999 20/122 37/129 73.3 % 0.57 [ 0.35, 0.93 ]
Wade 2002 7/191 13/189 26.7 % 0.53 [ 0.22, 1.31 ]
Subtotal (95% CI) 313 318 100.0 % 0.56 [ 0.37, 0.86 ]
Total events: 27 (Treatment), 50 (Control)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 2.65 (P = 0.0081)
3 Any reason
Doogan 1994 16/99 11/101 27.2 % 1.48 [ 0.73, 3.04 ]
Wade 2002 31/191 29/189 72.8 % 1.06 [ 0.66, 1.68 ]
Subtotal (95% CI) 290 290 100.0 % 1.17 [ 0.80, 1.73 ]
Total events: 47 (Treatment), 40 (Control)
Heterogeneity: Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
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Analysis 2.4. Comparison 2 SSRIs versus placebo, Outcome 4 Clinical response: UK vs USA/European-
based studies.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 2 SSRIs versus placebo
Outcome: 4 Clinical response: UK vs USA/European-based studies
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 UK-based studies
Doogan 1994 50/83 40/90 14.8 % 1.36 [ 1.01, 1.81 ]
Wade 2002 88/188 64/189 24.6 % 1.38 [ 1.08, 1.78 ]
Subtotal (95% CI) 271 279 39.3 % 1.37 [ 1.13, 1.66 ]
Total events: 138 (Treatment), 104 (Control)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 3.25 (P = 0.0012)
2 USA/European-based studies
Lepola 2001 Citalopram 84/159 37/77 19.2 % 1.10 [ 0.84, 1.45 ]
Lepola 2001 Escitalopram 99/155 37/77 19.0 % 1.33 [ 1.02, 1.73 ]
Malt 1999 74/122 60/129 22.4 % 1.30 [ 1.03, 1.65 ]
Subtotal (95% CI) 436 283 60.7 % 1.25 [ 1.08, 1.44 ]
Total events: 257 (Treatment), 134 (Control)
Heterogeneity: Chi2 = 1.18, df = 2 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 2.95 (P = 0.0032)
Total (95% CI) 707 562 100.0 % 1.30 [ 1.15, 1.46 ]
Total events: 395 (Treatment), 238 (Control)
Heterogeneity: Chi2 = 1.76, df = 4 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 4.36 (P = 0.000013)
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Analysis 2.5. Comparison 2 SSRIs versus placebo, Outcome 5 Clinical response: high quality studies.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 2 SSRIs versus placebo
Outcome: 5 Clinical response: high quality studies
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Doogan 1994 50/83 40/90 39.7 % 1.36 [ 1.01, 1.81 ]
Malt 1999 74/122 60/129 60.3 % 1.30 [ 1.03, 1.65 ]
Total (95% CI) 205 219 100.0 % 1.32 [ 1.10, 1.59 ]
Total events: 124 (Treatment), 100 (Control)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 3.03 (P = 0.0025)
0.1 0.2 0.5 1 2 5 10
Favours control Favours treatment
Analysis 2.6. Comparison 2 SSRIs versus placebo, Outcome 6 Clinical response: major depression diagnosis.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 2 SSRIs versus placebo
Outcome: 6 Clinical response: major depression diagnosis
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Doogan 1994 50/83 40/90 19.0 % 1.36 [ 1.01, 1.81 ]
Lepola 2001 Citalopram 84/159 37/77 24.7 % 1.10 [ 0.84, 1.45 ]
Lepola 2001 Escitalopram 99/155 37/77 24.5 % 1.33 [ 1.02, 1.73 ]
Wade 2002 88/188 64/189 31.7 % 1.38 [ 1.08, 1.78 ]
Total (95% CI) 585 433 100.0 % 1.29 [ 1.13, 1.48 ]
Total events: 321 (Treatment), 178 (Control)
Heterogeneity: Chi2 = 1.76, df = 3 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 3.76 (P = 0.00017)
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Analysis 2.7. Comparison 2 SSRIs versus placebo, Outcome 7 Depression symptoms: use of Montgomery-
Asberg scale.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 2 SSRIs versus placebo
Outcome: 7 Depression symptoms: use of Montgomery-Asberg scale





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Doogan 1994 83 12.5 (10.3) 90 15.3 (9.1) 14.0 % -2.80 [ -5.71, 0.11 ]
Lepola 2001 Citalopram 152 15.4 (10.3) 70 16.6 (9.1) 16.3 % -1.20 [ -3.89, 1.49 ]
Lepola 2001 Escitalopram 146 14.2 (10.3) 70 16.6 (9.1) 16.1 % -2.40 [ -5.11, 0.31 ]
Malt 1999 122 11.9 (10.3) 129 14 (10) 18.7 % -2.10 [ -4.61, 0.41 ]
Wade 2002 188 14.3 (9.1) 189 16.7 (9.1) 35.0 % -2.40 [ -4.24, -0.56 ]
Total (95% CI) 691 548 100.0 % -2.20 [ -3.29, -1.12 ]
Heterogeneity: Chi2 = 0.77, df = 4 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 3.98 (P = 0.000070)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 SSRIs versus placebo, Outcome 8 Clinical response: use of Montgomery-Asberg
scale.
Review: Antidepressants versus placebo for depression in primary care
Comparison: 2 SSRIs versus placebo
Outcome: 8 Clinical response: use of Montgomery-Asberg scale
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Doogan 1994 50/83 40/90 14.0 % 1.36 [ 1.01, 1.81 ]
Lepola 2001 Citalopram 84/159 37/77 18.1 % 1.10 [ 0.84, 1.45 ]
Lepola 2001 Escitalopram 99/155 37/77 18.0 % 1.33 [ 1.02, 1.73 ]
Malt 1999 74/122 60/129 21.2 % 1.30 [ 1.03, 1.65 ]
Wade 2002 103/188 79/189 28.7 % 1.31 [ 1.06, 1.62 ]
Total (95% CI) 707 562 100.0 % 1.28 [ 1.15, 1.43 ]
Total events: 410 (Treatment), 253 (Control)
Heterogeneity: Chi2 = 1.48, df = 4 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 4.34 (P = 0.000014)
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A D D I T I O N A L T A B L E S
Table 1. Quality Rating Scale items
No Item Components
1 Objectives and specification: Were main outcomes established
a priori?
0 = Objectives unclear
1 = Objectives clear but main outcomes not specified a priori 2
= Objectives clear with a priori specification of main outcomes
2 Adequacy of sample size:Were there enough completers in each
group?
0 = No/don’t know
2 = Yes
3 Planned duration of trial including follow up? 0 = < 3 months
1 = > 3 months < 6 months
2 = > 6 months
4 Method of allocation 0 = Not randomised and likely to be biased
1 = Partially or quasi randomised with some bias possible
2 = Randomised allocation
5 Concealment of allocation 0 = Not done or not reported
1 = Partial concealment reported
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Table 1. Quality Rating Scale items (Continued)
2 = Done adequately
6 Clear description of treatment (including doses of drugs) &
adjunctive treatment
0 = Main treatments not clearly described
1 = Inadequate details of main or adjunctive treatments
2 = Full details of main and adjunctive treatments
7 Blinding of subjects 0 = Not done
1 = Blinded but no test of blinding
2 = Blinded and integrity of blinding tested
8 Source of subjects described and representative sample re-
cruited?
0 = Source of subjects not described
1 = Source of subjects but unrepresentative sample e.g. in-
patients/specialist settings
2 = Source of subjects described plus representative sample
9 Use of diagnostic criteria (or clear specification of inclusion
criteria)
0 = None
1 = Diagnostic criteria or clear inclusion criteria
2 = Diagnostic criteria + specification of severity
10 Record of exclusion criteria and number of exclusions and re-
fusals reported?
0 = Criteria and number not reported
1 = Criteria or number of exclusions & refusals not reported
2 = Criteria and number of exclusions and refusals reported
11 Description of sample demographic characteristics? 0 = Little/no information (only age/sex)
1 = Basic description (e.g. marital status/ethnicity)
2 = Full description (e.g. socio-economic status/clinical his-
tory)
12 Blinding of assessor 0 = Not done
1 = Blinded but no test of blinding
2 = Blinded and integrity of blinding tested
13 Assessment of compliance with experimental treatments (in-
cluding adherence to therapy)
0 = Not assessed
1 = Assessed for some experimental treatments
2 = Assessed for all experimental treatments
14 Details on side effects 0 = Inadequate details
1 = Recorded by group but details inadequate
2 = Full side effect profiles by group
15 Record of number and reasons for withdrawal by group 0 = No information on withdrawals by group
1 = Withdrawals by group reported without reason
2 = Withdrawals and reason by group
16 Outcome measures described clearly or use of validated instru-
ments
0 = Outcomes not described clearly
1= Some outcomes not clearly described
2= Outcomes described or valid & reliable instruments used
59Antidepressants versus placebo for depression in primary care (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Quality Rating Scale items (Continued)
17 Information on comparability and adjustment for differences
in analysis
0= No information on comparability
1= Some info on comparability with appropriate adjustment
2= Sufficient comparability info with appropriate adjustment
18 Inclusion of withdrawals in analysis (ITT or endpoint) 0 = Not included or not reported
1 =Withdrawals included in analysis by estimation of outcome
2 = Withdrawals followed up and included in analysis
19 Presentation of results with inclusion of data for re-analysis of
main outcomes (e.g. SDs)
0 = Inadequate presentation
1= Adequate
2 = Comprehensive
20 Appropriate statistical analysis (including correction for mul-
tiple tests where applicable)
0 = Inappropriate
1 = Mainly appropriate
2 = Appropriate and comprehensive
21 Conclusions justified 0 = No
1 = Partially
2 = Yes
22 Declaration of interests (e.g. source of funding) 0 = No
2 = Yes
Notes:
1=Details on how the allocation codewas protected from those
involved in patient recruitment may be achieved by having
allocation done by a central independent body, or protection
of code (e.g. sealed opaque envelopes).
2= Source of subjects refers to the setting in which subjects
were found (e.g. inpatients, outpatients, general practice, com-
munity etc).
3= Test of integrity of blinding is normally done by asking
participants to guess their allocated group. Results can be com-
pared to those which would be expected by chance.
4= Whether or not the decision to initiate an antidepressant
was based strictly on the primary care practitioners judgment
that there was clinical depression warranting treatment rather
than insisting that criteria for a specific diagnosis, such asmajor
depressive disorder, be established
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A P P E N D I C E S
Appendix 1. Search of the CCDANCTR-Studies Register
CCDANCTR-Studies - searched on 24 September 2007
Intervention = (Antidepress* or “Monoamine Oxidase Inhibitors” or “Selective Serotonin Reuptake Inhibitors” or “Tricyclic Drugs”
or Acetylcarnitine or Alaproclate or Amersergide or Amiflamine or Amineptine or Amitriptyline or Amoxapine or Befloxatone or
Benactyzine or Brofaromine or Bupropion or Butriptyline or Caroxazone or Chlorpoxiten or Cilosamine or Cimoxatone or Citalo-
pram or Clomipramine or Clorgyline or Clorimipramine or Clovoxamine or Deanol or Demexiptiline or Deprenyl or Desipramine
or Dibenzipin or Diclofensine or Dothiepin or Doxepin or Duloxetine or Escitalopram or Etoperidone or Femoxetine or Fluotracen
or Fluoxetine or Fluparoxan or Fluvoxamine or Idazoxan or Imipramine or Iprindol* or Iproniazid or isocarboxazid or Litoxetin*
or Lofepramin* or Maprotilin* or Medifoxamin* or Melitracen or Metapramin* or Mianserin or Milnacipran or Minaprin* or Mir-
tazapin* or Moclobemid* or Nefazodon* or Nialamid* or Nomifensin* or Nortriptylin* or Noxiptilin* or Opipramol or Oxaflozan*
or Oxaprotilin* or Pargylin* or Paroxetin* or Phenelzin* or Piribedil or Pirlindol* or Pivagabin* or Prosulprid* or Protriptylin* or
Quinupramin* or Reboxetin* or Rolipram or Sertralin* or Setiptilin* or Teniloxin* or Tetrindol* or Thiazesim or Thozalinon* or
Tianeptin* or Toloxaton* or Tomoxetin* or Tranylcypromin* or Trazodon* or Trimipramin* or Venlafaxin* or Viloxazin* or Viqualin*
or Zimeldin*)
And Intervention = Placebo*
And Diagnosis = (Depress* or Dysthymi* or “Adjustment Disorder*” or “Mood Disorder*” or “Affective Disorder” or “Affective
Symptoms”)
And Setting = (“General Practice” or “Primary Care” or “Community Mental Health” or “Family Practice” or “Health Maintenance
Organization” or HMO or Home or “University Clinic” or Private or Ambulatory) And Age Group = Adult
Appendix 2. Search of the CCDANCTR-References Register
CCDANCTR-References - searched on 24 September 2007
Free-text = (Antidepress* or “Monoamine Oxidase Inhibitors” or “Selective Serotonin Reuptake Inhibitors” or “Tricyclic Drugs” or
Acetylcarnitine or Alaproclate or Amersergide or Amiflamine or Amineptine or Amitriptyline or Amoxapine or Befloxatone or Ben-
actyzine or Brofaromine or Bupropion or Butriptyline or Caroxazone or Chlorpoxiten or Cilosamine or Cimoxatone or Citalopram
or Clomipramine or Clorgyline or Clorimipramine or Clovoxamine or Deanol or Demexiptiline or Deprenyl or Desipramine or
Dibenzipin or Diclofensine or Dothiepin or Doxepin or Duloxetine or Escitalopram or Etoperidone or Femoxetine or Fluotracen
or Fluoxetine or Fluparoxan or Fluvoxamine or Idazoxan or Imipramine or Iprindol* or Iproniazid or isocarboxazid or Litoxetin*
or Lofepramin* or Maprotilin* or Medifoxamin* or Melitracen or Metapramin* or Mianserin or Milnacipran or Minaprin* or Mir-
tazapin* or Moclobemid* or Nefazodon* or Nialamid* or Nomifensin* or Nortriptylin* or Noxiptilin* or Opipramol or Oxaflozan*
or Oxaprotilin* or Pargylin* or Paroxetin* or Phenelzin* or Piribedil or Pirlindol* or Pivagabin* or Prosulprid* or Protriptylin* or
Quinupramin* or Reboxetin* or Rolipram or Sertralin* or Setiptilin* or Teniloxin* or Tetrindol* or Thiazesim or Thozalinon* or
Tianeptin* or Toloxaton* or Tomoxetin* or Tranylcypromin* or Trazodon* or Trimipramin* or Venlafaxin* or Viloxazin* or Viqualin*
or Zimeldin*) And Free-text= Placebo* And Keyword = (Depress* or Dysthymi* or “Adjustment Disorder*” or “Mood Disorder*” or
“Affective Disorder” or “Affective Symptoms”) And Free-text = (“General Practice” or “Primary Care” or “Community Mental Health”
or “Family Practice” or “Health Maintenance Organization” or HMO or Home or “University Clinic” or Private or Ambulatory)
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24 September 2007 New citation required and conclusions have changed Substantive amendment
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